<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1d3 20150301//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 39.96?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5703543</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0188333</article-id><article-id pub-id-type="publisher-id">PONE-D-17-31829</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Virology</subject><subj-group><subject>Viral Replication</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Biological Cultures</subject><subj-group><subject>Cell Lines</subject><subj-group><subject>Vero Cells</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Genetics</subject><subj-group><subject>Gene expression</subject><subj-group><subject>Gene regulation</subject><subj-group><subject>Small interfering RNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Nucleic acids</subject><subj-group><subject>RNA</subject><subj-group><subject>Non-coding RNA</subject><subj-group><subject>Small interfering RNAs</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Orthomyxoviruses</subject><subj-group><subject>Influenza viruses</subject><subj-group><subject>Influenza A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Infectious Disease Control</subject><subj-group><subject>Vaccines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Biochemistry</subject><subj-group><subject>Proteins</subject><subj-group><subject>DNA-binding proteins</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical microbiology</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Hepatitis viruses</subject><subj-group><subject>Hepatitis A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and health sciences</subject><subj-group><subject>Pathology and laboratory medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial pathogens</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Hepatitis viruses</subject><subj-group><subject>Hepatitis A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral pathogens</subject><subj-group><subject>Hepatitis viruses</subject><subj-group><subject>Hepatitis A virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and life sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>RNA viruses</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Zika Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Medical Microbiology</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Zika Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pathology and Laboratory Medicine</subject><subj-group><subject>Pathogens</subject><subj-group><subject>Microbial Pathogens</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Zika Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Organisms</subject><subj-group><subject>Viruses</subject><subj-group><subject>Viral Pathogens</subject><subj-group><subject>Flaviviruses</subject><subj-group><subject>Zika Virus</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>A universal mammalian vaccine cell line substrate</article-title><alt-title alt-title-type="running-head">Universal vaccine cell substrates</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Murray</surname><given-names>Jackelyn</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Validation</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0001-8475-9337</contrib-id><name><surname>Todd</surname><given-names>Kyle V.</given-names></name><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-6755-5233</contrib-id><name><surname>Bakre</surname><given-names>Abhijeet</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Software</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0003-4713-2484</contrib-id><name><surname>Orr-Burks</surname><given-names>Nichole</given-names></name><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Visualization</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Jones</surname><given-names>Les</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Validation</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><name><surname>Wu</surname><given-names>Weilin</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"/></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2924-9956</contrib-id><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="corresp" rid="cor001">*</xref><xref ref-type="aff" rid="aff001"/></contrib></contrib-group><aff id="aff001"><addr-line>Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA, United States of America</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Jin</surname><given-names>Dong-Yan</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>University of Hong Kong, HONG KONG</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>ratripp@uga.edu</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>11</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>11</issue><elocation-id>e0188333</elocation-id><history><date date-type="received"><day>30</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>3</day><month>11</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Murray et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Murray et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0188333.pdf"/><abstract><p>Using genome-wide small interfering RNA (siRNA) screens for poliovirus, influenza A virus and rotavirus, we validated the top 6 gene hits PV, RV or IAV to search for host genes that when knocked-down (KD) enhanced virus permissiveness and replication over wild type Vero cells or HEp-2 cells. The enhanced virus replication was tested for 12 viruses and ranged from 2-fold to &#x0003e;1000-fold. There were variations in virus-specific replication (strain differences) across the cell lines examined. Some host genes (CNTD2, COQ9, GCGR, NDUFA9, NEU2, PYCR1, SEC16G, SVOPL, ZFYVE9, and ZNF205) showed that KD resulted in enhanced virus replication. These findings advance platform-enabling vaccine technology, the creation of diagnostic cells substrates, and are informative about the host mechanisms that affect virus replication in mammalian cells.</p></abstract><funding-group><award-group id="award001"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>HHSN272201400004C</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2924-9956</contrib-id><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/100008065</institution-id><institution>Georgia Research Alliance</institution></institution-wrap></funding-source><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2924-9956</contrib-id><name><surname>Tripp</surname><given-names>Ralph A.</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and analysis decision to publish, or preparation of this manuscript. This work was in part supported by the Center of Excellence for influenza Research and Surveillance (HHSN272201500004C), the Bill and Melinda Gates foundation, and the Georgia Research Alliance (GRA). The GRA is an independent nonprofit organization that works in partnership with the University System of Georgia and Georgia&#x02019;s Department of Economic Development.</funding-statement></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="17"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and its Supporting Information files.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and its Supporting Information files.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Vero cells, established from an African green monkey (non-human primate; NHP) are commonly used during poliovirus (PV), rotavirus (RV) and in some influenza A virus (IAV) vaccines [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0188333.ref010" ref-type="bibr">10</xref>]. A fortuitous deletion corresponding to the type 1 interferon (IFN) loci renders Vero cells susceptible to many viruses [<xref rid="pone.0188333.ref011" ref-type="bibr">11</xref>]. Egg-based vaccine production is the current method for vaccines like IAV, but is time-consuming, expensive and cannot respond rapidly to newly emerging strains. Mammalian cell culture-based vaccines can overcome these limitations, allowing for rapid scale up of vaccines, reduce production and purification costs, and exhibit equivalent or higher vaccine and efficacy in both immunocompetent and allergic individuals. As such, Vero cells are being used to make seasonal IAV vaccines due to variants that arise by antigenic drift [<xref rid="pone.0188333.ref012" ref-type="bibr">12</xref>]. One option for developing influenza vaccines is to create a vaccine cell line that is permissive for a large cohort of influenza subtypes [<xref rid="pone.0188333.ref012" ref-type="bibr">12</xref>]. Infection with a range of IAVs will promote reassortment of viral segments, leading to a mixture of diverse species, which can be used for vaccination. Achieving this capability could transform vaccinology.</p><p>Viruses co-opt host cells for their replication. Viruses must employ aspects of the host cellular machinery to translate viral mRNA, and to avoid host defenses in order to replicate. Additionally, viral strategies to replicate include the use of non-coding RNAs, the manipulation of translation factors, as well as modification of host cell microRNAs that regulate genes [<xref rid="pone.0188333.ref013" ref-type="bibr">13</xref>, <xref rid="pone.0188333.ref014" ref-type="bibr">14</xref>]. Using small interfering RNA technology (siRNA) it is possible to knock-down (KD) host genes affecting virus replication allowing one to determine pro- and anti-viral genes [<xref rid="pone.0188333.ref015" ref-type="bibr">15</xref>]. A general approach in creating a universal vaccine cell line is to ablate host cell defenses, and/or create or improved cell tropism. Thus, the host-resistance genes to poliovirus (PV), influenza A virus (IAV) and rotavirus (RV) in Vero cells were identified using siRNAs [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0188333.ref003" ref-type="bibr">3</xref>, <xref rid="pone.0188333.ref016" ref-type="bibr">16</xref>&#x02013;<xref rid="pone.0188333.ref018" ref-type="bibr">18</xref>]. The results show that one can increase virus replication without altering antigenicity [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0188333.ref018" ref-type="bibr">18</xref>, <xref rid="pone.0188333.ref019" ref-type="bibr">19</xref>]. Once the host genes needed for virus replication are validated, it is possible with clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 reagents to knock-out (KO) host genes with goal of gene editing cells to improve viral antigen and/or increase viral replication with the long-term goal of creating enhanced vaccine cells lines [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0188333.ref003" ref-type="bibr">3</xref>].</p><p>The studies examined here determined if KD of PV genes [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>], IAV genes [<xref rid="pone.0188333.ref017" ref-type="bibr">17</xref>, <xref rid="pone.0188333.ref018" ref-type="bibr">18</xref>], or RV genes [<xref rid="pone.0188333.ref003" ref-type="bibr">3</xref>] (Tables <xref ref-type="table" rid="pone.0188333.t001">1</xref>&#x02013;<xref ref-type="table" rid="pone.0188333.t002">2</xref>) would increase virus replication as determined by plaque assay in either Vero cell or HEp-2 cells (<xref ref-type="table" rid="pone.0188333.t003">Table 3</xref>). An aim was to determine if there were host genes which when silenced would enhance virus replication. We tested several RNA viruses including influenza A/WSN/1933 (IAV), poliovirus Sabin-2 (PV), rotavirus/G3P[<xref rid="pone.0188333.ref006" ref-type="bibr">6</xref>]/BB (RV), influenza B/Malaysia/2506/2004 (IBV), Dengue virus type 1, Hawaii (DENV), Yellow fever virus 17 D vaccine (YFV), Hepatitis A virus (HAV), Coxsackie virus B5 (EV71), mumps virus (MuV), rubella virus (RUBV), and a DNA virus, Varicella zoster virus (VZV). The results identified genes that when KD allowed for enhanced viral permissiveness and replication as determined by plaque assay or ELISA across viral families. Specifically, there were several host genes which enhanced virus replication when CNTD2, COQ9, GCGR, NDUFA9, NEU2, PYCR1, SEC16G, SVOPL, ZFYVE9, and ZNF205 genes were KD in Vero cells (<xref ref-type="table" rid="pone.0188333.t003">Table 3</xref>). The findings suggest that KD of many of the genes examined (<xref ref-type="table" rid="pone.0188333.t001">Table 1</xref>) might be useful to make a universal cell line, though KD of more than one gene identified was not examined in this study.</p><table-wrap id="pone.0188333.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0188333.t001</object-id><label>Table 1</label><caption><title>Top 6 genes that alter replication of poliovirus (PV), rotavirus (RV) or influenza A virus (IAV).</title></caption><alternatives><graphic id="pone.0188333.t001g" xlink:href="pone.0188333.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" rowspan="1" colspan="1">Virus</th><th align="center" rowspan="1" colspan="1">Gene name</th><th align="center" rowspan="1" colspan="1">Gene symbol</th></tr></thead><tbody><tr><td align="center" rowspan="6" colspan="1">PV</td><td align="center" rowspan="1" colspan="1">butyrophilin subfamily 2 member A1</td><td align="center" rowspan="1" colspan="1">BTN2A1</td></tr><tr><td align="center" rowspan="1" colspan="1">cyclin N-terminal domain containing 2</td><td align="center" rowspan="1" colspan="1">CNTD2</td></tr><tr><td align="center" rowspan="1" colspan="1">E1A binding</td><td align="center" rowspan="1" colspan="1">EP300</td></tr><tr><td align="center" rowspan="1" colspan="1">glucagon receptor</td><td align="center" rowspan="1" colspan="1">GCGR</td></tr><tr><td align="center" rowspan="1" colspan="1">sec61 translocon gamma subunit</td><td align="center" rowspan="1" colspan="1">SEC61G</td></tr><tr><td align="center" rowspan="1" colspan="1">zinc finger protein 205</td><td align="center" rowspan="1" colspan="1">ZNF205</td></tr><tr><td align="center" rowspan="6" colspan="1">RV</td><td align="center" rowspan="1" colspan="1">coenzyme Q9</td><td align="center" rowspan="1" colspan="1">COQ9</td></tr><tr><td align="center" rowspan="1" colspan="1">N-acetyl transfer 9 (putative)</td><td align="center" rowspan="1" colspan="1">NAT9</td></tr><tr><td align="center" rowspan="1" colspan="1">NADH: Ubiquinone oxidoreductase subunit A9</td><td align="center" rowspan="1" colspan="1">NDUFA9</td></tr><tr><td align="center" rowspan="1" colspan="1">neuraminidase 2</td><td align="center" rowspan="1" colspan="1">NEU2</td></tr><tr><td align="center" rowspan="1" colspan="1">synaptic vesicle-2 related protein like</td><td align="center" rowspan="1" colspan="1">SVOPL</td></tr><tr><td align="center" rowspan="1" colspan="1">RAD51 associated protein</td><td align="center" rowspan="1" colspan="1">RAD51AP1</td></tr><tr><td align="center" rowspan="6" colspan="1">IAV</td><td align="center" rowspan="1" colspan="1">coenzyme Q9</td><td align="center" rowspan="1" colspan="1">COQ9</td></tr><tr><td align="center" rowspan="1" colspan="1">NADH: Ubiquinone oxidoreductase subunit A9</td><td align="center" rowspan="1" colspan="1">NDUFA9</td></tr><tr><td align="center" rowspan="1" colspan="1">phospholipase A2 group 1B</td><td align="center" rowspan="1" colspan="1">PLA2G1B</td></tr><tr><td align="center" rowspan="1" colspan="1">pyrroline-5-carboxylate reductase 1</td><td align="center" rowspan="1" colspan="1">PYCR1</td></tr><tr><td align="center" rowspan="1" colspan="1">zinc finger FYVE- type containing 9</td><td align="center" rowspan="1" colspan="1">ZFYVE9</td></tr><tr><td align="center" rowspan="1" colspan="1">zinc finger protein 205</td><td align="center" rowspan="1" colspan="1">ZNF205</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>The top six genes that were identified from a genome-wide siRNA screen for poliovirus (PV), rotavirus (RV) and influenza A virus (IAV).</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0188333.t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0188333.t002</object-id><label>Table 2</label><caption><title>qRT-PCR validation of siRNA-mediated gene KD in Vero cells.</title></caption><alternatives><graphic id="pone.0188333.t002g" xlink:href="pone.0188333.t002"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="4" rowspan="1"><underline>Percent expression</underline></th><th align="left" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" colspan="2" rowspan="1"><underline>NTC</underline></th><th align="center" colspan="2" rowspan="1"><underline>siRNA treatment</underline></th><th align="left" rowspan="1" colspan="1">Adjusted P <underline>Value</underline></th></tr><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1">Replicate 1</th><th align="center" rowspan="1" colspan="1">Replicate 2</th><th align="center" rowspan="1" colspan="1">Replicate 1</th><th align="center" rowspan="1" colspan="1">Replicate 2</th><th align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">BTN2A1</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="center" rowspan="1" colspan="1">0.03</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">CNTD2</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.04</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">COQ9</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">2.37</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">EMX2</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">1.57</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">EP300</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.86</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">FGF2</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">3.67</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">GCGR</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.11</td><td align="center" rowspan="1" colspan="1">0.05</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">NAT9</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">1.08</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">NDUFA9</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.88</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">NEU2</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">PLA2G1B</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">PYCR1</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.01</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">RAD51AP1</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">SEC61G</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">STRADA</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">SVOPL</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">ZFYVE9</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr><tr><td align="left" rowspan="1" colspan="1">ZNF205</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">100.00</td><td align="center" rowspan="1" colspan="1">0.00</td><td align="center" rowspan="1" colspan="1">0.02</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.0001</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p>Vero cells were transfected with siRNAs against listed genes (50nM). Total RNA was isolated and treated with DNAse I to remove genomic DNA, reverse transcribed using oligo dT, and expression determined relative to GAPDH using custom Vero-specific primers for each gene. Amplification conditions were optimized as needed and amplicons were validated via Sanger sequencing. BTN2A1&#x02014;butyrophilin subfamily 2 member A1; CNTD2&#x02014;cyclin N-terminal domain containing 2; COQ9&#x02014;coenzyme Q9; EMX2&#x02014;empty spiracles homeobox 2; EP300&#x02014;E1A binding protein; FGF2&#x02014;fibroblast growth factor 2; GCGR- glucagon receptor; NAT9- N-acetyl transferase 9 (putative); NEU2-Neuraminidase 2; PLA2G1B - phospholipase A2 group IB; PYCR1&#x02014;pyrroline-5-carboxylate reductase 1; RAD51AP1&#x02014;RAD51 associated protein 1; SEC61G - SEC61 translocon gamma subunit; SVOPL&#x02014;SVOP like protein; ZFYVE9&#x02014;zinc finger FYVE-type containing 9; ZNF205&#x02014;Zinc finger protein 205. Gene expression is shown as percent. All comparisons were done using 2-way ANOVA and post hoc-Sidak test at &#x003b1; = 0.05.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone.0188333.t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0188333.t003</object-id><label>Table 3</label><caption><title>siRNA gene KD modulates replication of several viruses.</title></caption><alternatives><graphic id="pone.0188333.t003g" xlink:href="pone.0188333.t003"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"><underline>Vero cells</underline></th><th align="center" rowspan="1" colspan="1"><underline>HEp-2 cells</underline></th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1"><italic>BTN2A1</italic></td><td align="center" rowspan="1" colspan="1">PV, DENV, MuV, ZIKV<xref ref-type="table-fn" rid="t003fn002">*</xref></td><td align="center" rowspan="1" colspan="1">MuV, YFV</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>CNTD2</italic></td><td align="center" rowspan="1" colspan="1">PV, HAV</td><td align="center" rowspan="1" colspan="1">EV71, HAV</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>COQ9</italic></td><td align="center" rowspan="1" colspan="1">YFV, HAV</td><td align="center" rowspan="1" colspan="1">DENV, IBV<xref ref-type="table-fn" rid="t003fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>EMX2</italic></td><td align="center" rowspan="1" colspan="1">RV</td><td align="center" rowspan="1" colspan="1">EV71, HAV</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>EP300</italic></td><td align="center" rowspan="1" colspan="1">RC, EV71, YFV, VSV</td><td align="center" rowspan="1" colspan="1">EV71, HAV, IBV<xref ref-type="table-fn" rid="t003fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>GCGR</italic></td><td align="center" rowspan="1" colspan="1">PV, YFV, HAV, ZIKV<xref ref-type="table-fn" rid="t003fn002">*</xref></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>PLA2GB1</italic></td><td align="center" rowspan="1" colspan="1">YFV</td><td align="center" rowspan="1" colspan="1">EV71</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>PYCR1</italic></td><td align="center" rowspan="1" colspan="1">IAV, HAV, ZIKV<xref ref-type="table-fn" rid="t003fn002">*</xref></td><td align="center" rowspan="1" colspan="1">HAV, VZV</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>NAT9</italic></td><td align="center" rowspan="1" colspan="1">RV, ZIKV<xref ref-type="table-fn" rid="t003fn002">*</xref></td><td align="center" rowspan="1" colspan="1">UBV<xref ref-type="table-fn" rid="t003fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>NDUFA9</italic></td><td align="center" rowspan="1" colspan="1">RV</td><td align="center" rowspan="1" colspan="1">HAV, IBV<xref ref-type="table-fn" rid="t003fn002">*</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>NEU2</italic></td><td align="center" rowspan="1" colspan="1">HAV</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>RAD51AP1</italic></td><td align="center" rowspan="1" colspan="1">YFV, ZIKV<xref ref-type="table-fn" rid="t003fn002">*</xref></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SEC61G</italic></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">HAV</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>STRADA</italic></td><td align="center" rowspan="1" colspan="1">DENV</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>SVOPL</italic></td><td align="center" rowspan="1" colspan="1">DENV, MuV</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"><italic>ZNF205</italic></td><td align="center" rowspan="1" colspan="1">RUBV, ZIKV<xref ref-type="table-fn" rid="t003fn002">*</xref></td><td align="center" rowspan="1" colspan="1">HAV</td></tr><tr><td align="left" rowspan="1" colspan="1"><italic>ZFYVE9</italic></td><td align="center" rowspan="1" colspan="1">DENV, ZIKV<xref ref-type="table-fn" rid="t003fn002">*</xref></td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table></alternatives><table-wrap-foot><fn id="t003fn001"><p>BTN2A1- butyrophilin subfamily 2 member A1; CNTD2- cyclin N-terminal domain containing 2; COQ9&#x02014;ubiquinone biosynthesis protein, EMX2&#x02014;homeobox-containing transcription factor, EP300- E1A binding protein; GCGR&#x02014;G-protein coupled receptor for glucagon, PLA2GB1- epithelial-cell-derived group 1B phospholipase A2, PYCR1- pyrroline-5-carboxylate reductase 1; NAT9&#x02014;N-Acetyltransferase 9, NDUFA9&#x02014;NADH-coenzyme Q Reductase, NEU2&#x02014;neuraminidase 2, RAD51AP1&#x02014;RAD51 associated protein, SEC61G - SEC61 translocon gamma subunit; STRADA&#x02014;STE20-related kinase adapter protein alpha, SOPL&#x02014;a paralog of the SVOP gene that encodes synaptic vesicle 2-related protein; ZNF205&#x02014;zinc finger protein 205; ZFYVE9&#x02014;zinc finger FYVE domain-containing protein 9, IAV-Influenza A virus; PV&#x02014;poliovirus; RV- rotavirus 3; IBV&#x02014;influenza B virus; DENV&#x02014;dengue virus type 1; YFV&#x02014;Yellow fever virus 17D strain; HAV&#x02014;hepatitis A virus; EV71&#x02014;Coxsackie virus B5; MuV -mumps virus, RUBV&#x02014;rubella virus; VZV&#x02014;varicella zoster virus. Based on significantly different error bars representing &#x000b1;SEM from three independent experiments p&#x0003c;0.001.</p></fn><fn id="t003fn002"><p>* = results from one independent plaque assay where n = 3 wells/gene KD were evaluated and the fold-change over the NTC.</p></fn></table-wrap-foot></table-wrap></sec><sec sec-type="results" id="sec002"><title>Results</title><p>The ability to connect systems biology with host gene discovery to aid our understanding of the virus-host network is essential for creating a universal vaccine cell line. We used complementary approaches and data sets from several high-throughput screens for IAV [<xref rid="pone.0188333.ref018" ref-type="bibr">18</xref>], PV [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>] and RV [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0188333.ref003" ref-type="bibr">3</xref>] to arrive at a multidimensional view of virus-host networks. We screened the 6 top host genes for PV, RV or IAV that enhanced virus replication (<xref ref-type="table" rid="pone.0188333.t001">Table 1</xref>), and tested if gene KD using siRNAs in Vero cells or HEp-2 cell lines would affect host cell permissiveness and allow for enhanced virus replication for 12 different viruses compared to control WT cells or cells transfected with a non-targeting (NTC) control siRNA. All siRNAs tested were ON-TARGETplus siRNAs designed to be seed-region optimized, leading to minimal off-target effects [<xref rid="pone.0188333.ref020" ref-type="bibr">20</xref>]. The genome-wide screens for PV, IAV and RV showed no or negligible off-target effects. All host genes targeted for KD in Vero cells or HEp-2 cells were &#x02265;95% silenced before virus infection (<xref ref-type="table" rid="pone.0188333.t002">Table 2</xref>).</p><p>For these studies, the PV strain was Sabin-2 as the World Health Organization recently endorsed elimination of Sabin -1 strains [<xref rid="pone.0188333.ref002" ref-type="bibr">2</xref>]. We noted virus strain differences in the magnitude of PV replication while switching from Sabin-1 to Sabin-2, particularly in the use of host genes involved in the ability of these strains to replicate which we do not fully understand [<xref rid="pone.0188333.ref021" ref-type="bibr">21</xref>]. In Vero cells, the highest PV replication resulted from KD of CNTD2 (~4-fold) followed by KD of BTN2A1 and GCGR (~3-fold), and EP300, NAT9, RAD51AP1, SEC61G and ZNF205 that ranged from ~2- increases (<xref ref-type="fig" rid="pone.0188333.g001">Fig 1A</xref>). In HEp-2 cells, the highest PV replication occurred for KD of CNTD2 (3-fold), where BTN2A1, EP300, GCGR, and ZNF205 KD resulted in &#x0003e;2-3-fold increases. We also examined the ELISA results for RV (<xref ref-type="fig" rid="pone.0188333.g001">Fig 1B</xref>). An ELISA was necessary since RV does not plaque well in Vero cells [<xref rid="pone.0188333.ref022" ref-type="bibr">22</xref>, <xref rid="pone.0188333.ref023" ref-type="bibr">23</xref>]. The highest absorbance (480 nm) was for KD of EMX2, EP300, NAT9 and NDUFA9 genes which was significantly above NTC background. We also evaluated the top 6 genes for IAV replication in Vero cells (<xref ref-type="fig" rid="pone.0188333.g001">Fig 1C</xref>). IAVs are divided into subtypes based on two proteins on the surface of the virus: the hemagglutinin (H) and the neuraminidase (N). There are 18 different hemagglutinin subtypes and 11 different neuraminidase subtypes [<xref rid="pone.0188333.ref024" ref-type="bibr">24</xref>]. The top genes identified that when KD increased IAV replication were CNTD2, PLA2G1B and PYCR1 (2-4-fold) followed by ZFYVE9 (~2-fold).</p><fig id="pone.0188333.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0188333.g001</object-id><label>Fig 1</label><caption><title>Genome-wide siRNA screening identifies 18 genes that modulate replication of poliovirus (PV), rotavirus (RV) or influenza A virus (IAV).</title><p>Vero cells were reverse transfected with non-targeting control (NTC) / gene specific on-target plus (OTP) siRNAs (50nM) for 48h followed by infection with PV (A), RV (B) or IAV (C). Effect of gene knockdown on viral replication is shown as fold-change relative to NTC from pooled samples. Data represent plaque numbers (A and C) and absorbance (&#x003bb; = 450nm) for (B). Error bars represent &#x000b1;SEM from three independent experiments. * p&#x0003c;0.05 **p&#x0003c;0.01 ***p&#x0003c;0.001 ****p&#x0003c;0.0001.</p></caption><graphic xlink:href="pone.0188333.g001"/></fig><p>We examined five RNA virus families (<italic>Picornaviridae</italic>, <italic>Flaviviridae</italic>, <italic>Togaviridae</italic>, <italic>Orthomyxoviridae</italic>, <italic>Reoviridae</italic>, <italic>and Paramyxoviridae)</italic> and 1 DNA virus family, <italic>i</italic>.<italic>e</italic>. <italic>Herpesviridae</italic> in our efforts to develop a universal cell line. All of these viruses were tested in Vero cell and HEp-2 cell lines that were targeted by siRNA to KD the top 6 gene hits (<xref ref-type="table" rid="pone.0188333.t003">Table 3</xref>).</p><p>EV71 is a picornavirus [<xref rid="pone.0188333.ref025" ref-type="bibr">25</xref>] and was propagated in Vero cells (<xref ref-type="fig" rid="pone.0188333.g002">Fig 2A</xref>) and in HEp-2 cells (<xref ref-type="fig" rid="pone.0188333.g002">Fig 2B</xref>). In Vero cells, there was a ~ 8-fold increase in virus replication following KD of host gene EP300. As the results are expressed as fold-change over NTC, all &#x02265;2-fold increase in replication was considered notable. Other notable host genes affecting EV71 replication were CNTD2, EMX2, GCGR, NAT9, NDUFA9, PLA2G1B, PYCR1, SEC61G, SOPL and ZNF205 (<xref ref-type="fig" rid="pone.0188333.g002">Fig 2A</xref>). For HEp-2 cells, KD of CNTD2, EMX2, EP300, and PLA2G1C increased EV71 virus replication 2-3-fold, while there was a ~2-fold increase when STRADA and ZNF205 were KD (<xref ref-type="fig" rid="pone.0188333.g002">Fig 2B</xref>). Little is known about how these host genes and how they may affect EV71 replication. It is possible that KD of more than one gene may have synergistic or additive effects; however this is not well-understood and was not tested in this study. The Cyclin N-Terminal Domain Containing 2 (CNTD2) gene is orphan cyclin where it has a predominantly nuclear location and it is implicated in transcription regulation as described for other cyclins [<xref rid="pone.0188333.ref026" ref-type="bibr">26</xref>]. It is known that the EP300 gene behaves as a histone acetyltransferase and regulates transcription [<xref rid="pone.0188333.ref027" ref-type="bibr">27</xref>]. EMX2 is a gene that encodes a homeobox-containing transcription factor and possibly regulates mRNA transport or translation [<xref rid="pone.0188333.ref028" ref-type="bibr">28</xref>]. The glucagon receptor gene (GCGR) has a role in glucose homeostasis and is implicated to modulate the activity of adenylate cyclase [<xref rid="pone.0188333.ref029" ref-type="bibr">29</xref>, <xref rid="pone.0188333.ref030" ref-type="bibr">30</xref>]. The N-acetyltransferase 9 (NAT9) gene is involved in the catalysis of the transfer of an acetyl group to a nitrogen atom on the acceptor molecule [<xref rid="pone.0188333.ref031" ref-type="bibr">31</xref>]. NDUFA9 is a subunit of the hydrophobic protein fraction of the NADH: ubiquinone oxidoreductase, the first enzyme complex in the electron transport chain located in the inner mitochondrial membrane [<xref rid="pone.0188333.ref032" ref-type="bibr">32</xref>, <xref rid="pone.0188333.ref033" ref-type="bibr">33</xref>]. Phospholipase A2, group 1B (PLA2G1B) is an enzyme that catalyzes the release of fatty acids from glycero-3-phosphocholines [<xref rid="pone.0188333.ref034" ref-type="bibr">34</xref>]. Pyrroline-5-carboxylate reductase (PYCR1) is a mitochondrial enzyme that catalyzes proline biosynthesis reducing pyrroline-5-carboxylate to L-proline [<xref rid="pone.0188333.ref035" ref-type="bibr">35</xref>]. Protein transport protein Sec61 subunit gamma (SEC61G) may function to aid protein translocation in the endoplasmic reticulum [<xref rid="pone.0188333.ref036" ref-type="bibr">36</xref>]. The SVOPL gene is poorly annotated and thought to function as a substrate-specific transmembrane transporter [<xref rid="pone.0188333.ref037" ref-type="bibr">37</xref>]. There is experimental evidence at the protein level that zinc finger protein (ZNF)-205 may be involved in transcriptional regulation [<xref rid="pone.0188333.ref038" ref-type="bibr">38</xref>]. For HEp-2 cells (<xref ref-type="fig" rid="pone.0188333.g002">Fig 2B</xref>), KD of CNTD2, EMX2, EP300 and PLA2G1B had a 2-3-fold increases in EV71 replication.</p><fig id="pone.0188333.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0188333.g002</object-id><label>Fig 2</label><caption><title>siRNA identifies cell type specificity of genes that modulate replication of EV71 and HAV.</title><p>Vero / HEp2-c cells were reverse transfected with non-targeting control (NTC) / gene specific on-target plus (OTP) siRNAs (50nM) for48h followed by infection with EV71 (A and B) or Hepatitis A virus (HAV) (C and D). Effect of gene knockdown on viral replication is shown as fold -change relative to NTC from pooled samples. Error bars represent &#x000b1;SEM from two independent experiments. * p&#x0003c;0.05 **p&#x0003c;0.01 ***p&#x0003c;0.001 ****p&#x0003c;0.0001.</p></caption><graphic xlink:href="pone.0188333.g002"/></fig><p>HAV viruses are in the picornavirus family [<xref rid="pone.0188333.ref039" ref-type="bibr">39</xref>]. HAV replicated to substantially higher levels in Vero cells (<xref ref-type="fig" rid="pone.0188333.g002">Fig 2C</xref>), and to elevated levels in HEp-2 cells (<xref ref-type="fig" rid="pone.0188333.g002">Fig 2D</xref>). KD of CNTD2, COQ9, GCGR, NEU2, and PYCR1 genes in Vero cells led to ~100 - &#x0003e;200-fold increases in replication. Similarly, NDUFA9, NEU2, SEC61G, and ZNF205 were found to be important for replication in HEp-2 cells (<xref ref-type="fig" rid="pone.0188333.g002">Fig 2D</xref>). KD of NDUFA9, NEU2, SEC61G, and ZNF205 led to 50-100-fold increase in HAV replication. Of note, the NADH dehydrogenase 1 alpha subcomplex subunit 9 (NDUFA9) gene is thought to be an accessory subunit of the mitochondrial membrane respiratory chain NADH dehydrogenase [<xref rid="pone.0188333.ref032" ref-type="bibr">32</xref>]. The NEU2 gene catalyzes the removal of sialic acid from glycoproteins and oligosaccharides [<xref rid="pone.0188333.ref040" ref-type="bibr">40</xref>]. It is not clear how these host genes affect HAV replication. EP300 functions as histone acetyltransferase and regulates transcription via chromatin remodeling [<xref rid="pone.0188333.ref041" ref-type="bibr">41</xref>].</p><p>Dengue virus (DENV), a member of the <italic>Flaviviridae</italic> family, is transmitted by <italic>Aedes</italic> mosquitos [<xref rid="pone.0188333.ref042" ref-type="bibr">42</xref>]. Based on antibody neutralization, four serotypes (DENV-1, DENV-2, DENV-3, and DENV-4) are evident [<xref rid="pone.0188333.ref043" ref-type="bibr">43</xref>]. KD of BTN2A1, STRADA, SVOPL and ZFYVE9 increased DENV-1 replication in Vero cells (<xref ref-type="fig" rid="pone.0188333.g003">Fig 3A</xref>), and KD of COQ9, GCGR, and SVOPL substantially increased virus replication in HEp-2 cells (<xref ref-type="fig" rid="pone.0188333.g003">Fig 3B</xref>). These findings indicate that Vero cells and Hep-2 cells are permissive to DENV-1 with 2-3-fold higher virus replication following KD of key genes in HEp-2 cells.</p><fig id="pone.0188333.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0188333.g003</object-id><label>Fig 3</label><caption><title>siRNA identifies cell type specificity of genes that modulate replication of Dengue virus (DENV) and Yellow fever virus (YFV).</title><p>Vero / HEp2-c cells were reverse transfected with non-targeting control (NTC) / gene specific on-target plus (OTP) siRNAs (50nM) for 48h followed by infection with DENV (A and B) or YFV (C and D). Effect of gene knockdown on viral replication is shown as fold-change relative to NTC from pooled samples. Error bars represent &#x000b1;SEM from two independent experiments. * p&#x0003c;0.05 **p&#x0003c;0.01 ***p&#x0003c;0.001 ****p&#x0003c;0.0001.</p></caption><graphic xlink:href="pone.0188333.g003"/></fig><p>Yellow fever virus (YFV) is also transmitted to humans by Aedes mosquitos [<xref rid="pone.0188333.ref044" ref-type="bibr">44</xref>]. As expected, IFN-deficient Vero cells were more susceptible compared to HEp-2 cells. KD of COQ9, EP300, GCGR, PLA2G1B or RAD51AP1 resulted in enhanced YFV replication (~50-100-fold) in Vero cells (<xref ref-type="fig" rid="pone.0188333.g003">Fig 3C</xref>). KD of PLA2G1B had the greatest effect on virus replication, ~100-fold over NTC. YFV replication in HEp-2 cells was diminished relative to Vero cells, with peak titers following KD of BTN2A1 ~40-fold (<xref ref-type="fig" rid="pone.0188333.g003">Fig 3D</xref>). As noted, most gene functions as they relate to virus replication remain unknown.</p><p>Mumps virus (MuV) is typically propagated in Hep-2 cells [<xref rid="pone.0188333.ref045" ref-type="bibr">45</xref>] as it does not grow well in Vero cells [<xref rid="pone.0188333.ref046" ref-type="bibr">46</xref>]. We examined the permissiveness of MUV for Vero cells and HEp-2 cells having KD of select host genes (<xref ref-type="table" rid="pone.0188333.t003">Table 3</xref>). KD of BTN2A1 and SVOPL dramatically increased MUV propagation in Vero cells (<xref ref-type="fig" rid="pone.0188333.g004">Fig 4A</xref>), whereas only KD of BTN2A1 was associated with enhanced virus replication in HEp-2 cells (<xref ref-type="fig" rid="pone.0188333.g004">Fig 4B</xref>). KD of BTN2A1 and SVOPL led to increased MUV replication ~10-fold in Vero cells. BTN2A1 KD in HEp-2 cells enhanced MUV replication ~20-fold (<xref ref-type="fig" rid="pone.0188333.g004">Fig 4B</xref>).</p><fig id="pone.0188333.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0188333.g004</object-id><label>Fig 4</label><caption><title>siRNA identifies cell type specificity of genes that modulate replication of mumps virus (MuV) and varicella zoster virus (VZV).</title><p>Vero / HEp2-c cells were reverse transfected with non-targeting control (NTC) / gene specific on-target plus (OTP) siRNAs (50nM) for 48h followed by infection with MuV (A and B) or VZV (C) (MOI = 0.1). Effect of gene knockdown on viral replication is shown as fold-change relative to NTC from pooled samples. Error bars represent &#x000b1;SEM from two independent experiments. * p&#x0003c;0.05 **p&#x0003c;0.01 ***p&#x0003c;0.001 ****p&#x0003c;0.0001.</p></caption><graphic xlink:href="pone.0188333.g004"/></fig><p>Varicella zoster (VZV) is the causative agent of chickenpox/shingles and is a DNA virus and member of &#x003b1;-herpesvirus family [<xref rid="pone.0188333.ref047" ref-type="bibr">47</xref>, <xref rid="pone.0188333.ref048" ref-type="bibr">48</xref>]. VZV is a component of several vaccines including the combined measles, mumps, rubella, and varicella (MMRV) vaccine [<xref rid="pone.0188333.ref047" ref-type="bibr">47</xref>], and newer vaccines such as live-attenuated herpes zoster vaccine for adults &#x0003e;50 years [<xref rid="pone.0188333.ref049" ref-type="bibr">49</xref>]. Vero cells were superior to HEp-2 cells as Vero cells could propagate VZV, thus they were chosen for analysis. KD of CNTD2 and EP300 resulted in a 10-30-fold increase in VZV replication.</p><p>Rubella virus (RUBV) is in the family Togaviridae [<xref rid="pone.0188333.ref050" ref-type="bibr">50</xref>]. RUBV is an important human pathogen associated with it birth defects, known congenital rubella syndrome (CRS), but through use of vaccines rubella and CRS are controlled [<xref rid="pone.0188333.ref050" ref-type="bibr">50</xref>]. We investigated if RUBV would grow in Vero cell and HEp-2 cells, but found it could only be propagated in Vero cells (<xref ref-type="fig" rid="pone.0188333.g005">Fig 5A</xref>). This is likely related to features of the antiviral IFN pathway [<xref rid="pone.0188333.ref051" ref-type="bibr">51</xref>] but was not specifically investigated. KD of GCGR, PYCR1, SVOPL, or ZNF205 led to 10-&#x0003e;100-fold increases in RUBV, where KD of ZNF205 led to highest increases in RUBV.</p><fig id="pone.0188333.g005" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0188333.g005</object-id><label>Fig 5</label><caption><title>siRNA identifies genes that modulate replication of rubella virus (RUBV) and influenza B virus (IBV) and Zika virus (ZIKV).</title><p>Vero cells were reverse transfected with non-targeting control (NTC) / gene specific on-target plus (OTP) siRNAs (50nM) for 48h followed by infection with RUBV (A) or IBV (B) or ZIKV (strain PVRABC) (C). Effect of gene knockdown on viral replication is shown as fold-change relative to NTC from pooled samples. Error bars represent &#x000b1;SEM from two independent experiments. * p&#x0003c;0.05 **p&#x0003c;0.01 ***p&#x0003c;0.001 ****p&#x0003c;0.0001.</p></caption><graphic xlink:href="pone.0188333.g005"/></fig><p>There are four types of influenza viruses, A, B, C and D, where human influenza A and B viruses cause seasonal epidemics and influenza type C infections generally cause a mild respiratory illness, and influenza type D viruses primarily affect cattle and are not known to infect or cause illness in people [<xref rid="pone.0188333.ref052" ref-type="bibr">52</xref>]. Currently, two lineages of type B influenza virus (IBV) co-circulate in the world, thus the key host genes that affect IBV replication were determined in Vero cells which are an FDA-approved vaccine cell line used to propagate flu viruses (<xref ref-type="fig" rid="pone.0188333.g005">Fig 5B</xref>). KD of BTN2A1, COQ9, EP300, FGF2, GCGR, NAT9, and NDUFA9 genes had a ~2-3-fold increased IBV replication. <xref ref-type="fig" rid="pone.0188333.g005">Fig 5B</xref> shows the results from one independent plaque assay where n = 3 wells/gene KD were evaluated, and the fold-change over the NTC is shown. Lastly, Zika virus (ZIKV) which belongs to the Flaviviridae family and is spread by mosquitoes [<xref rid="pone.0188333.ref053" ref-type="bibr">53</xref>], was evaluated for replication in Vero cells (<xref ref-type="fig" rid="pone.0188333.g005">Fig 5C</xref>) as ZIKV did not replicate in HEP-2 cells. Two ZIKV strains (PVRABC59 and lbH30656) were examined. These ZIKV strains only grew in Vero cells which is consistent with their IFN-sensitivity in HEp-2 cells [<xref rid="pone.0188333.ref054" ref-type="bibr">54</xref>]. In Vero cells, KD of PYCR1, RAD51AP1, and ZNF205 lead to a 200-1000-fold increase in ZIKV virus titers, with the highest increases for KD of ZNF-205. The role for these genes restricting virus ZIKV replication is not known. However, it has been shown that loss of PYCR1 function leads to decreased mitochondrial membrane potential and increased adequate susceptibility to apoptosis under oxidative stress [<xref rid="pone.0188333.ref055" ref-type="bibr">55</xref>]. These finding show that there are a spectrum host genes that restrict cell tropism and virus replication. All raw data used to summarize data shown in Figs <xref ref-type="fig" rid="pone.0188333.g001">1</xref>&#x02013;<xref ref-type="fig" rid="pone.0188333.g005">5</xref> is available as supplementary data (<xref ref-type="supplementary-material" rid="pone.0188333.s001">S1 Fig</xref>).</p></sec><sec sec-type="conclusions" id="sec003"><title>Discussion</title><p>To make a universal cell line that is receptive to a range of viruses, one should identify host genes that influence intrinsic immunity and help determine restriction or permissiveness toward virus infection and replication. There is convincing evidence that many viruses have evolved not only to avoid the apoptosis-mediated viral elimination, but also to exploit and even activate it to facilitate their lifecycle. As one example, influenza proteins NS1 and PB1-F2 act as apoptosis promoters [<xref rid="pone.0188333.ref056" ref-type="bibr">56</xref>, <xref rid="pone.0188333.ref057" ref-type="bibr">57</xref>], and it was found that caspase-3 activation was needed for efficient influenza virus replication [<xref rid="pone.0188333.ref058" ref-type="bibr">58</xref>&#x02013;<xref rid="pone.0188333.ref061" ref-type="bibr">61</xref>]. Each virus has found its way to survive, and co-opt the host cell for replication.</p><p>Vero cells are one of the first continuous cell lines that were used for vaccine production which was helped by their lack of anti-viral IFN signaling [<xref rid="pone.0188333.ref008" ref-type="bibr">8</xref>, <xref rid="pone.0188333.ref011" ref-type="bibr">11</xref>]. This feature makes the Vero cell line more permissive for a wide spectrum of viruses [<xref rid="pone.0188333.ref006" ref-type="bibr">6</xref>, <xref rid="pone.0188333.ref062" ref-type="bibr">62</xref>]. In this study, we KD the top genes discovered from screening and validating a siRNA genome-wide screen of IAV, RV, or PV (Tables <xref ref-type="table" rid="pone.0188333.t001">1</xref>&#x02013;<xref ref-type="table" rid="pone.0188333.t002">2</xref>) with the goal of finding the top host genes in Vero cells and HEp-2 cells (<xref ref-type="table" rid="pone.0188333.t003">Table 3</xref>) that could be used to create a universal vaccine cell line. We have shown that Vero cells transfected with siRNAs to KD BTN2A1, CNTD2, EP300, GCGR, PYCR1 and ZNF205 will support enhanced virus replication of most viruses examined here including PV, RV, IAV, DENV, HAV, EV71, MUV, RUBV, YFV, VZV, or ZIKV.</p><p>Stand out findings from the results are that 1) it may be possible to create an enhanced universal cell line permissive for many viruses, 2) the Vero cell lines are generally better at propagating viruses than HEp-2 cells, 3) there is increased virus replication is in the KD cell lines, and 4) virus strain differences affect the outcome and magnitude of virus replication. For example, this was evident between ZIKV strains PVRABC59 and lbH30656 which had nearly 5 x10<sup>7</sup> PFU/mL and 2 x 10<sup>6</sup> PFU/mL between strains, respectively, using the same propagation conditions. The reasons for these differences are not presently known.</p><p>In this study, we evaluated viruses with known strain variation, and expected these differences to affect the host genes linked to virus replication as was discovered for PV studies [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>]. Another example of antigenically distinct viruses are DENV which has been classified into four individual serotypes (DENV 1&#x02013;4) [<xref rid="pone.0188333.ref063" ref-type="bibr">63</xref>, <xref rid="pone.0188333.ref064" ref-type="bibr">64</xref>]. DENV like many other viruses has evolved multiple mechanisms to evade the innate immune response and increase virus replication. It is clear that universal vaccination can have major impacts on diseases such as PV, MUV, and RUBV [<xref rid="pone.0188333.ref065" ref-type="bibr">65</xref>, <xref rid="pone.0188333.ref066" ref-type="bibr">66</xref>]. One the other hand, vaccine-preventable diseases such as IAV continue to cause significant disease because of use of our inadequate use of vaccines [<xref rid="pone.0188333.ref067" ref-type="bibr">67</xref>]. Advances in vaccine technology are now providing the opportunity to target new diseases and create enhanced vaccine cell lines. Making a cell line that allows for reduced costs is a rate-limiting feature that will drive prioritization and going forward. For example, RV is a common cause of severe gastroenteritis in children. RV causes a large disease burden ($US 2 billion in 2007) [<xref rid="pone.0188333.ref004" ref-type="bibr">4</xref>], where morbidity and mortality occurs in malnourished infants in low and middle income countries. Vaccines typically confer 85&#x02013;100% protection against severe disease, while in low income regions protection is around 46&#x02013;77%, thus the RV vaccination program must rely upon sustained vaccine efficacy level against evolving strains. Cost effectiveness depends largely on the RV mortality rate and the price of the vaccine in relation to the per capita gross domestic product. An enhanced vaccine cell line like Vero cells could save millions of dollars and improve the quality life worldwide.</p></sec><sec sec-type="materials|methods" id="sec004"><title>Materials and methods</title><sec id="sec005"><title>Cells and viruses</title><p>A siRNA screen was performed using Vero cells (African green monkey kidney cells; received from the Centers of Disease Control and Prevention (CDC, Atlanta) who obtained them from the Serum Institute of India (SI) [<xref rid="pone.0188333.ref068" ref-type="bibr">68</xref>] and HEp-2 cells (human laryngeal carcinoma, HeLa-derivative; received from the Centers of Disease Control and Prevention, Atlanta [<xref rid="pone.0188333.ref069" ref-type="bibr">69</xref>]. Vero cells were cultured at 37&#x000b0;C and 5% CO2 in Dulbecco&#x02019;s modified Eagle&#x02019;s medium (DMEM; HyClone, GE Healthcare) supplemented with 10% fetal bovine serum (FBS; HyClone). The same passage number of Vero cells and HEp-2 cells was used in validation studies to minimize differences and aid interpretation. A master cell bank was created to ensure that all experiments were performed using a consistent low number of cell passages. PV (Sabin-2) was obtained from National Institute for Biological Standards and Control, Health Protection Agency, Potters Bar, United Kingdom. RV strain RV3 was obtained from the CDC and propagated in MA104 cells (rhesus monkey epithelial cell line; clone 1, ATCC CRL-2378.1 [<xref rid="pone.0188333.ref070" ref-type="bibr">70</xref>]. Peak ELISA antigen levels was determined as previously described [<xref rid="pone.0188333.ref003" ref-type="bibr">3</xref>]. Briefly, Vero cells were infected with RV (MOI = 0.2), the cells fixed prior to performing an immunofluorescent ELISA. For immunofluorescent staining, fixed plates were stained using a primary polyclonal rabbit anti-RV antibody (Rab A-SA11, Australia) the plates washed, blocked, and were then a goat anti-rabbit Alexa 488 antibody used for detection with a Beckman Coulter Paradigm spectrophotometer. Additionally, the percent of infected cells per well was determined relative to that of the non-targeting control by additional staining of the plate with DAPI to detect cell nuclei and scanning on a Cellomics Array scanner. IAV (A/WSN 33) and influenza B/Malaysia/2506/2004 were propagated in embryonated chicken eggs. DENV-1 (Hawaii, BEI resources NR-82) was grown in Vero cells [<xref rid="pone.0188333.ref071" ref-type="bibr">71</xref>]. The YFV 17 D vaccine strain (BEI resources NR-116) was grown in Vero cells [<xref rid="pone.0188333.ref071" ref-type="bibr">71</xref>]. HAV (ATCC- VR-2266) was grown in MRC-145 cells [<xref rid="pone.0188333.ref072" ref-type="bibr">72</xref>]. Coxsackie Virus B5 (EV71; ATCC VR-185) was grown in Vero cells [<xref rid="pone.0188333.ref073" ref-type="bibr">73</xref>]. MUV virus (ATCC VR-1438) was grown in HEp-2 cells [<xref rid="pone.0188333.ref074" ref-type="bibr">74</xref>]. RUBV (ATCC VR-1359) was grown in Vero cells [<xref rid="pone.0188333.ref075" ref-type="bibr">75</xref>]. VZV (human herpesvirus 3 ATCC VR-1367) was grown in MRC-145 cells [<xref rid="pone.0188333.ref076" ref-type="bibr">76</xref>]. ZIKV (strains PVRABC59 and lbH30656 were tested) in Vero cells [<xref rid="pone.0188333.ref077" ref-type="bibr">77</xref>].</p></sec><sec id="sec006"><title>Cellular growth, viability and cytotoxicity</title><p>Vero and HEp-2 cells were screened for cellular viability and cytotoxicity following siRNA transfection by CellTiter96 Non-Radioactive Cell Proliferation Assay Kit and ToxiLight bioassay (Lonza, Walkersville, MD) following manufacturer&#x02019;s instructions. Cellular toxicity was evaluated at 0 and 48 h post-transfection. Data was normalized to siTOX control (100% cytotoxicity). siRNAs which resulted in &#x0003e;10% toxicity were excluded from the screen. Cell growth assessment revealed no significant differences in cell adherence or doubling time between KD and wild type cells.</p></sec><sec id="sec007"><title>Human siRNAs</title><p>ON-TARGETplus siRNAs (GE Healthcare, Lafayette, CO) combine sense-strand inactivation with a novel seed-region modification and were used to target the host genes of interest (<xref ref-type="table" rid="pone.0188333.t001">Table 1</xref>). Non-targeting controls allowed assessment of non-specific effects. Pooled siRNA controls were used for reduction of off-targeting with Vero cells, and for use with SMARTpool siRNA reagents that were used for validation.</p><p>siRNAs targeting the 18 host genes of interest (<xref ref-type="table" rid="pone.0188333.t001">Table 1</xref>) were reverse transfected in triplicate into HEp-2 cells or Vero cells at a final concentration of 50 nM using 0.3% DharmaFECT-4, and triplicate experiments were done three independent times unless noted otherwise. Briefly, On-TARGETplus siRNAs were mixed with DharmaFECT 4 reagent in serum-free medium (Opti-MEM; Invitrogen Inc., Carlsbad, CA) and incubated at room temperature for 20 min. A NTC siRNA (GE Healthcare) and a PV, RV or IAV type-specific positive siRNA control target were included [<xref rid="pone.0188333.ref078" ref-type="bibr">78</xref>]. Vero cells were subsequently added (9,000 cells/well) with DMEM supplemented with 10% FBS. Transfected cells were cultured at 37&#x000b0;C and 5% CO2. After 48h, the medium was removed and cells were infected with PV (MOI = 0.1) in DMEM supplemented with 2% FCS and 1% penicillin-streptomycin. In some cases, 24h pi; the plates were frozen at 80&#x000b0;C and stored until analysis of antigen content by ELISA. For siRNAs targeting the other viruses (<xref ref-type="table" rid="pone.0188333.t001">Table 1</xref>), similar methods were used [<xref rid="pone.0188333.ref001" ref-type="bibr">1</xref>, <xref rid="pone.0188333.ref018" ref-type="bibr">18</xref>]. The validated gene hits from IAV, PV and RV studies were analyzed for the top 6 PV, IAV virus, or RV hits, and several end-point assays [<xref rid="pone.0188333.ref019" ref-type="bibr">19</xref>] such as plaque assay were re-confirmed. For PV, RV and IAV, all assays used an endpoint of day 3 pi with a MOI = 0.1. ZIKV was at day 5 pi at MOI = 0.1. For all other others examined an endpoint of day 7&#x02013;10 pi was used. In all siRNA studies, there was &#x0003e;95 gene KD (<xref ref-type="table" rid="pone.0188333.t002">Table 2</xref>) which is consistent with the manufacturer assertions (Dharmacon GE).</p></sec><sec id="sec008"><title>RT-qPCR</title><p>qPCR was performed to evaluate that KD took place with each of the siRNAs [<xref rid="pone.0188333.ref079" ref-type="bibr">79</xref>]. We examined KD of the genes (<xref ref-type="table" rid="pone.0188333.t001">Table 1</xref>) in HEp-2 and Vero cells using the comparative CT method (&#x00394;&#x00394;CT) for relative quantitation for measuring siRNA-induced KD of a particular gene using TaqMan, and &#x0003e;95% gene KD was confirmed (<xref ref-type="table" rid="pone.0188333.t002">Table 2</xref>). The RNA from the siRNA-transfected cells was assessed by measuring the RNA levels of the GAPDH gene, according to an endogenous 18S RNA. A NTC siRNA-transfected was also assessed to the experimental samples to assess the negative control samples. The &#x00394;&#x00394;CT was used to calculate the percent remaining gene expression and the percent knockdown. Since the Vero genome is not fully annotated, we designed Vero specific primers using available contigs, amplified the regions from normal Vero cDNA using high fidelity Q5 Polymerase (New England Biolabs) and cloned the inserts into TOPO TA vectors which were then sequence validated. Amplifications conditions were optimized as needed.</p></sec><sec id="sec009"><title>Statistics</title><p>The data are expressed as the fold-change over the non-targeting control, except for comparison of ZIKV strains which are mean of n = 3 experiments &#x000b1;SE. Statistical analyses were performed using GraphPad Prism software using one-way ANOVA (reporter studies) with post hoc Dunnett&#x02019;s test. Error bars represent &#x000b1;SEM of three independent experiments.</p></sec><sec id="sec010"><title>Ethics statement</title><p>The University of Georgia (UGA) Institutional Biosafety Committee approved all research involving embryonated chicken eggs. The embryonated eggs were obtained from the Southeast Poultry Research center at UGA. For propagation of influenza viruses, specific pathogen-free eggs were used 7&#x02013;8 days after fertilization.</p></sec></sec><sec sec-type="supplementary-material" id="sec011"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0188333.s001"><label>S1 Fig</label><caption><title>Raw viral titers/ absorbance values for all figures in the manuscript.</title><p>Supplementary excel file contains all raw data from viral titer assays in this manuscript. All assays were done in multiple technical replicates with either two or three biological replicates. Each worksheet summarizes fold change in viral titers relative to NTC for Vero and /or HEp-2 cells. Worksheet labels indicate virus-cell line-Figure panel.</p><p>(XLSX)</p></caption><media xlink:href="pone.0188333.s001.xlsx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0188333.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>van der Sanden</surname><given-names>SM</given-names></name>, <name><surname>Wu</surname><given-names>W</given-names></name>, <name><surname>Dybdahl-Sissoko</surname><given-names>N</given-names></name>, <name><surname>Weldon</surname><given-names>WC</given-names></name>, <name><surname>Brooks</surname><given-names>P</given-names></name>, <name><surname>O'Donnell</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game</article-title>. <source>Journal of virology</source>. <year>2015</year>;<volume>90</volume>(<issue>4</issue>):<fpage>1694</fpage>&#x02013;<lpage>704</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.01464-15">10.1128/JVI.01464-15</ext-link></comment> ; PubMed Central PMCID: PMC4733985.<?supplied-pmid 26581994?><pub-id pub-id-type="pmid">26581994</pub-id></mixed-citation></ref><ref id="pone.0188333.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Modlin</surname><given-names>J</given-names></name>, <name><surname>Wenger</surname><given-names>J</given-names></name>. <article-title>Achieving and maintaining polio eradication&#x02014;new strategies</article-title>. <source>The New England journal of medicine</source>. <year>2014</year>;<volume>371</volume>(<issue>16</issue>):<fpage>1476</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1056/NEJMp1407783">10.1056/NEJMp1407783</ext-link></comment> .<?supplied-pmid 25317869?><pub-id pub-id-type="pmid">25317869</pub-id></mixed-citation></ref><ref id="pone.0188333.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Wu</surname><given-names>W</given-names></name>, <name><surname>Orr-Burks</surname><given-names>N</given-names></name>, <name><surname>Karpilow</surname><given-names>J</given-names></name>, <name><surname>Tripp</surname><given-names>RA</given-names></name>. <article-title>Development of improved vaccine cell lines against rotavirus</article-title>. <source>Scientific data</source>. <year>2017</year>;<volume>4</volume>:<fpage>170021</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/sdata.2017.21">10.1038/sdata.2017.21</ext-link></comment> ; PubMed Central PMCID: PMC5332008.<?supplied-pmid 28248921?><pub-id pub-id-type="pmid">28248921</pub-id></mixed-citation></ref><ref id="pone.0188333.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Grimwood</surname><given-names>K</given-names></name>, <name><surname>Lambert</surname><given-names>SB</given-names></name>, <name><surname>Milne</surname><given-names>RJ</given-names></name>. <article-title>Rotavirus infections and vaccines: burden of illness and potential impact of vaccination</article-title>. <source>Paediatric drugs</source>. <year>2010</year>;<volume>12</volume>(<issue>4</issue>):<fpage>235</fpage>&#x02013;<lpage>56</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2165/11537200-000000000-00000">10.2165/11537200-000000000-00000</ext-link></comment> .<?supplied-pmid 20593908?><pub-id pub-id-type="pmid">20593908</pub-id></mixed-citation></ref><ref id="pone.0188333.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>PN</given-names></name>, <name><surname>Mundt</surname><given-names>W</given-names></name>, <name><surname>Kistner</surname><given-names>O</given-names></name>, <name><surname>Howard</surname><given-names>MK</given-names></name>. <article-title>Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines</article-title>. <source>Expert review of vaccines</source>. <year>2009</year>;<volume>8</volume>(<issue>5</issue>):<fpage>607</fpage>&#x02013;<lpage>18</lpage>. Epub 2009/04/29. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/erv.09.19">10.1586/erv.09.19</ext-link></comment> .<?supplied-pmid 19397417?><pub-id pub-id-type="pmid">19397417</pub-id></mixed-citation></ref><ref id="pone.0188333.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Audsley</surname><given-names>JM</given-names></name>, <name><surname>Tannock</surname><given-names>GA</given-names></name>. <article-title>The growth of attenuated influenza vaccine donor strains in continuous cell lines</article-title>. <source>Journal of virological methods</source>. <year>2005</year>;<volume>123</volume>(<issue>2</issue>):<fpage>187</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jviromet.2004.09.015">10.1016/j.jviromet.2004.09.015</ext-link></comment> .<?supplied-pmid 15620401?><pub-id pub-id-type="pmid">15620401</pub-id></mixed-citation></ref><ref id="pone.0188333.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>PN</given-names></name>, <name><surname>Portsmouth</surname><given-names>D</given-names></name>, <name><surname>Ehrlich</surname><given-names>HJ</given-names></name>. <article-title>Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development</article-title>. <source>Expert review of vaccines</source>. <year>2013</year>;<volume>12</volume>(<issue>4</issue>):<fpage>395</fpage>&#x02013;<lpage>413</lpage>. Epub 2013/04/09. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/erv.13.21">10.1586/erv.13.21</ext-link></comment> .<?supplied-pmid 23560920?><pub-id pub-id-type="pmid">23560920</pub-id></mixed-citation></ref><ref id="pone.0188333.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Montomoli</surname><given-names>E</given-names></name>, <name><surname>Khadang</surname><given-names>B</given-names></name>, <name><surname>Piccirella</surname><given-names>S</given-names></name>, <name><surname>Trombetta</surname><given-names>C</given-names></name>, <name><surname>Mennitto</surname><given-names>E</given-names></name>, <name><surname>Manini</surname><given-names>I</given-names></name>, <etal>et al</etal>
<article-title>Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production</article-title>. <source>Expert review of vaccines</source>. <year>2012</year>;<volume>11</volume>(<issue>5</issue>):<fpage>587</fpage>&#x02013;<lpage>94</lpage>. Epub 2012/07/26. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/erv.12.24">10.1586/erv.12.24</ext-link></comment> .<?supplied-pmid 22827244?><pub-id pub-id-type="pmid">22827244</pub-id></mixed-citation></ref><ref id="pone.0188333.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Barrett</surname><given-names>PN</given-names></name>, <name><surname>Portsmouth</surname><given-names>D</given-names></name>, <name><surname>Ehrlich</surname><given-names>HJ</given-names></name>. <article-title>Developing cell culture-derived pandemic vaccines</article-title>. <source>Current opinion in molecular therapeutics</source>. <year>2010</year>;<volume>12</volume>(<issue>1</issue>):<fpage>21</fpage>&#x02013;<lpage>30</lpage>. Epub 2010/02/09. .<?supplied-pmid 20140813?><pub-id pub-id-type="pmid">20140813</pub-id></mixed-citation></ref><ref id="pone.0188333.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Horimoto</surname><given-names>T</given-names></name>, <name><surname>Kawaoka</surname><given-names>Y</given-names></name>. <article-title>Strategies for developing vaccines against H5N1 influenza A viruses</article-title>. <source>Trends in molecular medicine</source>. <year>2006</year>;<volume>12</volume>(<issue>11</issue>):<fpage>506</fpage>&#x02013;<lpage>14</lpage>. Epub 2006/10/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molmed.2006.09.003">10.1016/j.molmed.2006.09.003</ext-link></comment> .<?supplied-pmid 17011235?><pub-id pub-id-type="pmid">17011235</pub-id></mixed-citation></ref><ref id="pone.0188333.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Osada</surname><given-names>N</given-names></name>, <name><surname>Kohara</surname><given-names>A</given-names></name>, <name><surname>Yamaji</surname><given-names>T</given-names></name>, <name><surname>Hirayama</surname><given-names>N</given-names></name>, <name><surname>Kasai</surname><given-names>F</given-names></name>, <name><surname>Sekizuka</surname><given-names>T</given-names></name>, <etal>et al</etal>
<article-title>The genome landscape of the african green monkey kidney-derived vero cell line</article-title>. <source>DNA research: an international journal for rapid publication of reports on genes and genomes</source>. <year>2014</year>;<volume>21</volume>(<issue>6</issue>):<fpage>673</fpage>&#x02013;<lpage>83</lpage>. Epub 2014/10/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/dnares/dsu029">10.1093/dnares/dsu029</ext-link></comment> ; PubMed Central PMCID: PMCPMC4263300.<?supplied-pmid 25267831?><pub-id pub-id-type="pmid">25267831</pub-id></mixed-citation></ref><ref id="pone.0188333.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Weir</surname><given-names>JP</given-names></name>, <name><surname>Gruber</surname><given-names>MF</given-names></name>. <article-title>An overview of the regulation of influenza vaccines in the United States</article-title>. <source>Influenza and other respiratory viruses</source>. <year>2016</year>;<volume>10</volume>(<issue>5</issue>):<fpage>354</fpage>&#x02013;<lpage>60</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/irv.12383">10.1111/irv.12383</ext-link></comment> ; PubMed Central PMCID: PMC4947948.<?supplied-pmid 27426005?><pub-id pub-id-type="pmid">27426005</pub-id></mixed-citation></ref><ref id="pone.0188333.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Poltronieri</surname><given-names>P</given-names></name>, <name><surname>Sun</surname><given-names>B</given-names></name>, <name><surname>Mallardo</surname><given-names>M</given-names></name>. <article-title>RNA Viruses: RNA Roles in Pathogenesis, Coreplication and Viral Load</article-title>. <source>Current genomics</source>. <year>2015</year>;<volume>16</volume>(<issue>5</issue>):<fpage>327</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.2174/1389202916666150707160613">10.2174/1389202916666150707160613</ext-link></comment> ; PubMed Central PMCID: PMC4763971.<?supplied-pmid 27047253?><pub-id pub-id-type="pmid">27047253</pub-id></mixed-citation></ref><ref id="pone.0188333.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Ojha</surname><given-names>CR</given-names></name>, <name><surname>Rodriguez</surname><given-names>M</given-names></name>, <name><surname>Dever</surname><given-names>SM</given-names></name>, <name><surname>Mukhopadhyay</surname><given-names>R</given-names></name>, <name><surname>El-Hage</surname><given-names>N</given-names></name>. <article-title>Mammalian microRNA: an important modulator of host-pathogen interactions in human viral infections</article-title>. <source>Journal of biomedical science</source>. <year>2016</year>;<volume>23</volume>(<issue>1</issue>):<fpage>74</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s12929-016-0292-x">10.1186/s12929-016-0292-x</ext-link></comment> ; PubMed Central PMCID: PMC5081962.<?supplied-pmid 27784307?><pub-id pub-id-type="pmid">27784307</pub-id></mixed-citation></ref><ref id="pone.0188333.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>Li</surname><given-names>ML</given-names></name>, <name><surname>Weng</surname><given-names>KF</given-names></name>, <name><surname>Shih</surname><given-names>SR</given-names></name>, <name><surname>Brewer</surname><given-names>G</given-names></name>. <article-title>The evolving world of small RNAs from RNA viruses</article-title>. <source>Wiley interdisciplinary reviews RNA</source>. <year>2016</year>;<volume>7</volume>(<issue>5</issue>):<fpage>575</fpage>&#x02013;<lpage>88</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/wrna.1351">10.1002/wrna.1351</ext-link></comment> .<?supplied-pmid 27046163?><pub-id pub-id-type="pmid">27046163</pub-id></mixed-citation></ref><ref id="pone.0188333.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Bakre</surname><given-names>A</given-names></name>, <name><surname>Andersen</surname><given-names>LE</given-names></name>, <name><surname>Meliopoulos</surname><given-names>V</given-names></name>, <name><surname>Coleman</surname><given-names>K</given-names></name>, <name><surname>Yan</surname><given-names>X</given-names></name>, <name><surname>Brooks</surname><given-names>P</given-names></name>, <etal>et al</etal>
<article-title>Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs</article-title>. <source>PloS one</source>. <year>2013</year>;<volume>8</volume>(<issue>6</issue>):<fpage>e66796</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0066796">10.1371/journal.pone.0066796</ext-link></comment> ; PubMed Central PMCID: PMC3689682.<?supplied-pmid 23805279?><pub-id pub-id-type="pmid">23805279</pub-id></mixed-citation></ref><ref id="pone.0188333.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Meliopoulos</surname><given-names>VA</given-names></name>, <name><surname>Andersen</surname><given-names>LE</given-names></name>, <name><surname>Brooks</surname><given-names>P</given-names></name>, <name><surname>Yan</surname><given-names>X</given-names></name>, <name><surname>Bakre</surname><given-names>A</given-names></name>, <name><surname>Coleman</surname><given-names>JK</given-names></name>, <etal>et al</etal>
<article-title>MicroRNA regulation of human protease genes essential for influenza virus replication</article-title>. <source>PloS one</source>. <year>2012</year>;<volume>7</volume>(<issue>5</issue>):<fpage>e37169</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0037169">10.1371/journal.pone.0037169</ext-link></comment> ; PubMed Central PMCID: PMC3351457.<?supplied-pmid 22606348?><pub-id pub-id-type="pmid">22606348</pub-id></mixed-citation></ref><ref id="pone.0188333.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Meliopoulos</surname><given-names>VA</given-names></name>, <name><surname>Andersen</surname><given-names>LE</given-names></name>, <name><surname>Birrer</surname><given-names>KF</given-names></name>, <name><surname>Simpson</surname><given-names>KJ</given-names></name>, <name><surname>Lowenthal</surname><given-names>JW</given-names></name>, <name><surname>Bean</surname><given-names>AG</given-names></name>, <etal>et al</etal>
<article-title>Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens</article-title>. <source>FASEB journal: official publication of the Federation of American Societies for Experimental Biology</source>. <year>2012</year>;<volume>26</volume>(<issue>4</issue>):<fpage>1372</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1096/fj.11-193466">10.1096/fj.11-193466</ext-link></comment> ; PubMed Central PMCID: PMC3316894.<?supplied-pmid 22247330?><pub-id pub-id-type="pmid">22247330</pub-id></mixed-citation></ref><ref id="pone.0188333.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Tripp</surname><given-names>RA</given-names></name>, <name><surname>Mark Tompkins</surname><given-names>S</given-names></name>. <article-title>Antiviral effects of inhibiting host gene expression</article-title>. <source>Current topics in microbiology and immunology</source>. <year>2015</year>;<volume>386</volume>:<fpage>459</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/82_2014_409">10.1007/82_2014_409</ext-link></comment> .<?supplied-pmid 25007848?><pub-id pub-id-type="pmid">25007848</pub-id></mixed-citation></ref><ref id="pone.0188333.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Agrawal</surname><given-names>S</given-names></name>, <name><surname>Kandimalla</surname><given-names>ER</given-names></name>. <article-title>Role of Toll-like receptors in antisense and siRNA [corrected]</article-title>. <source>Nature biotechnology</source>. <year>2004</year>;<volume>22</volume>(<issue>12</issue>):<fpage>1533</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nbt1042">10.1038/nbt1042</ext-link></comment> .<?supplied-pmid 15583662?><pub-id pub-id-type="pmid">15583662</pub-id></mixed-citation></ref><ref id="pone.0188333.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>van der Sanden</surname><given-names>SM</given-names></name>, <name><surname>Wu</surname><given-names>W</given-names></name>, <name><surname>Dybdahl-Sissoko</surname><given-names>N</given-names></name>, <name><surname>Weldon</surname><given-names>WC</given-names></name>, <name><surname>Brooks</surname><given-names>P</given-names></name>, <name><surname>O'Donnell</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Engineering Enhanced Vaccine Cell Lines To Eradicate Vaccine-Preventable Diseases: the Polio End Game</article-title>. <source>Journal of virology</source>. <year>2016</year>;<volume>90</volume>(<issue>4</issue>):<fpage>1694</fpage>&#x02013;<lpage>704</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.01464-15">10.1128/JVI.01464-15</ext-link></comment> ; PubMed Central PMCID: PMC4733985.<?supplied-pmid 26581994?><pub-id pub-id-type="pmid">26581994</pub-id></mixed-citation></ref><ref id="pone.0188333.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Hughes</surname><given-names>JH</given-names></name>. <article-title>Physical and chemical methods for enhancing rapid detection of viruses and other agents</article-title>. <source>Clinical microbiology reviews</source>. <year>1993</year>;<volume>6</volume>(<issue>2</issue>):<fpage>150</fpage>&#x02013;<lpage>75</lpage>. ; PubMed Central PMCID: PMC358275.<?supplied-pmid 8472247?><pub-id pub-id-type="pmid">8472247</pub-id></mixed-citation></ref><ref id="pone.0188333.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Rao</surname><given-names>CD</given-names></name>, <name><surname>Reddy</surname><given-names>H</given-names></name>, <name><surname>Naidu</surname><given-names>JR</given-names></name>, <name><surname>Raghavendra</surname><given-names>A</given-names></name>, <name><surname>Radhika</surname><given-names>NS</given-names></name>, <name><surname>Karande</surname><given-names>A</given-names></name>. <article-title>An enzyme-linked immuno focus assay for rapid detection and enumeration, and a newborn mouse model for human non-polio enteroviruses associated with acute diarrhea</article-title>. <source>Journal of virological methods</source>. <year>2015</year>;<volume>224</volume>:<fpage>47</fpage>&#x02013;<lpage>52</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jviromet.2015.08.007">10.1016/j.jviromet.2015.08.007</ext-link></comment> .<?supplied-pmid 26300372?><pub-id pub-id-type="pmid">26300372</pub-id></mixed-citation></ref><ref id="pone.0188333.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Dormitzer</surname><given-names>PR</given-names></name>, <name><surname>Galli</surname><given-names>G</given-names></name>, <name><surname>Castellino</surname><given-names>F</given-names></name>, <name><surname>Golding</surname><given-names>H</given-names></name>, <name><surname>Khurana</surname><given-names>S</given-names></name>, <name><surname>Del Giudice</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Influenza vaccine immunology</article-title>. <source>Immunological reviews</source>. <year>2011</year>;<volume>239</volume>(<issue>1</issue>):<fpage>167</fpage>&#x02013;<lpage>77</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1600-065X.2010.00974.x">10.1111/j.1600-065X.2010.00974.x</ext-link></comment> .<?supplied-pmid 21198671?><pub-id pub-id-type="pmid">21198671</pub-id></mixed-citation></ref><ref id="pone.0188333.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>JX</given-names></name>, <name><surname>Jin</surname><given-names>PF</given-names></name>, <name><surname>Wang</surname><given-names>YX</given-names></name>, <name><surname>Zhu</surname><given-names>FC</given-names></name>. <article-title>Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine</article-title>. <source>Expert review of vaccines</source>. <year>2016</year>;<volume>15</volume>(<issue>7</issue>):<fpage>803</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/14760584.2016.1191357">10.1080/14760584.2016.1191357</ext-link></comment> .<?supplied-pmid 27206811?><pub-id pub-id-type="pmid">27206811</pub-id></mixed-citation></ref><ref id="pone.0188333.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Gasa</surname><given-names>L</given-names></name>, <name><surname>Sanchez-Botet</surname><given-names>A</given-names></name>, <name><surname>Quandt</surname><given-names>E</given-names></name>, <name><surname>Hern&#x000e1;ndez-Ortega</surname><given-names>S</given-names></name>, <name><surname>Jim&#x000e9;nez</surname><given-names>J</given-names></name>, <name><surname>Carrasco-Garc&#x000ed;a</surname><given-names>MA</given-names></name>, <etal>et al</etal>
<article-title>A systematic analysis of orphan cyclins reveals CNTD2 as a new oncogenic driver in lung cancer</article-title>. <source>Scientific Reports</source>. <year>2017</year>;<volume>7</volume>(<issue>1</issue>):<fpage>10228</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/s41598-017-10770-8">10.1038/s41598-017-10770-8</ext-link></comment>
<?supplied-pmid 28860486?><pub-id pub-id-type="pmid">28860486</pub-id></mixed-citation></ref><ref id="pone.0188333.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Ghosh</surname><given-names>AK</given-names></name>, <name><surname>Varga</surname><given-names>J</given-names></name>. <article-title>The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis</article-title>. <source>J Cell Physiol</source>. <year>2007</year>;<volume>213</volume>(<issue>3</issue>):<fpage>663</fpage>&#x02013;<lpage>71</lpage>. Epub 2007/06/15. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/jcp.21162">10.1002/jcp.21162</ext-link></comment> .<?supplied-pmid 17559085?><pub-id pub-id-type="pmid">17559085</pub-id></mixed-citation></ref><ref id="pone.0188333.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Brunelli</surname><given-names>S</given-names></name>, <name><surname>Faiella</surname><given-names>A</given-names></name>, <name><surname>Capra</surname><given-names>V</given-names></name>, <name><surname>Nigro</surname><given-names>V</given-names></name>, <name><surname>Simeone</surname><given-names>A</given-names></name>, <name><surname>Cama</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Germline mutations in the homeobox gene EMX2 in patients with severe schizencephaly</article-title>. <source>Nat Genet</source>. <year>1996</year>;<volume>12</volume>(<issue>1</issue>):<fpage>94</fpage>&#x02013;<lpage>6</lpage>. Epub 1996/01/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/ng0196-94">10.1038/ng0196-94</ext-link></comment> .<?supplied-pmid 8528262?><pub-id pub-id-type="pmid">8528262</pub-id></mixed-citation></ref><ref id="pone.0188333.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Zhang</surname><given-names>H</given-names></name>, <name><surname>Qiao</surname><given-names>A</given-names></name>, <name><surname>Yang</surname><given-names>D</given-names></name>, <name><surname>Yang</surname><given-names>L</given-names></name>, <name><surname>Dai</surname><given-names>A</given-names></name>, <name><surname>de Graaf</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Structure of the full-length glucagon class B G-protein-coupled receptor</article-title>. <source>Nature</source>. <year>2017</year>;<volume>546</volume>(<issue>7657</issue>):<fpage>259</fpage>&#x02013;<lpage>64</lpage>. Epub 2017/05/18. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nature22363">10.1038/nature22363</ext-link></comment> ; PubMed Central PMCID: PMCPMC5492955.<?supplied-pmid 28514451?><pub-id pub-id-type="pmid">28514451</pub-id></mixed-citation></ref><ref id="pone.0188333.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Roed</surname><given-names>SN</given-names></name>, <name><surname>Nohr</surname><given-names>AC</given-names></name>, <name><surname>Wismann</surname><given-names>P</given-names></name>, <name><surname>Iversen</surname><given-names>H</given-names></name>, <name><surname>Brauner-Osborne</surname><given-names>H</given-names></name>, <name><surname>Knudsen</surname><given-names>SM</given-names></name>, <etal>et al</etal>
<article-title>Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>(<issue>2</issue>):<fpage>1233</fpage>&#x02013;<lpage>43</lpage>. Epub 2014/12/03. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.M114.592436">10.1074/jbc.M114.592436</ext-link></comment> ; PubMed Central PMCID: PMCPMC4294488.<?supplied-pmid 25451942?><pub-id pub-id-type="pmid">25451942</pub-id></mixed-citation></ref><ref id="pone.0188333.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Zou</surname><given-names>X</given-names></name>, <name><surname>Ci</surname><given-names>HL</given-names></name>, <name><surname>Chen</surname><given-names>W</given-names></name>, <name><surname>Li</surname><given-names>YP</given-names></name>. [<article-title>Cloning and expression analysis of human N-acetyltransferase doman containing gene hNATL</article-title>]. <source>Fen Zi Xi Bao Sheng Wu Xue Bao</source>. <year>2006</year>;<volume>39</volume>(<issue>1</issue>):<fpage>22</fpage>&#x02013;<lpage>8</lpage>. Epub 2006/09/02. .<?supplied-pmid 16944568?><pub-id pub-id-type="pmid">16944568</pub-id></mixed-citation></ref><ref id="pone.0188333.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Stroud</surname><given-names>DA</given-names></name>, <name><surname>Formosa</surname><given-names>LE</given-names></name>, <name><surname>Wijeyeratne</surname><given-names>XW</given-names></name>, <name><surname>Nguyen</surname><given-names>TN</given-names></name>, <name><surname>Ryan</surname><given-names>MT</given-names></name>. <article-title>Gene knockout using transcription activator-like effector nucleases (TALENs) reveals that human NDUFA9 protein is essential for stabilizing the junction between membrane and matrix arms of complex I</article-title>. <source>J Biol Chem</source>. <year>2013</year>;<volume>288</volume>(<issue>3</issue>):<fpage>1685</fpage>&#x02013;<lpage>90</lpage>. Epub 2012/12/12. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.C112.436766">10.1074/jbc.C112.436766</ext-link></comment> ; PubMed Central PMCID: PMCPMC3548478.<?supplied-pmid 23223238?><pub-id pub-id-type="pmid">23223238</pub-id></mixed-citation></ref><ref id="pone.0188333.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Baertling</surname><given-names>F</given-names></name>, <name><surname>Sanchez-Caballero</surname><given-names>L</given-names></name>, <name><surname>van den Brand</surname><given-names>MA</given-names></name>, <name><surname>Fung</surname><given-names>CW</given-names></name>, <name><surname>Chan</surname><given-names>SH</given-names></name>, <name><surname>Wong</surname><given-names>VC</given-names></name>, <etal>et al</etal>
<article-title>NDUFA9 point mutations cause a variable mitochondrial complex I assembly defect</article-title>. <source>Clinical genetics</source>. <year>2017</year> Epub 2017/07/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/cge.13089">10.1111/cge.13089</ext-link></comment> .<?supplied-pmid 28671271?><pub-id pub-id-type="pmid">28671271</pub-id></mixed-citation></ref><ref id="pone.0188333.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Dennis</surname><given-names>EA</given-names></name>. <article-title>Diversity of group types, regulation, and function of phospholipase A2</article-title>. <source>J Biol Chem</source>. <year>1994</year>;<volume>269</volume>(<issue>18</issue>):<fpage>13057</fpage>&#x02013;<lpage>60</lpage>. Epub 1994/05/06. .<?supplied-pmid 8175726?><pub-id pub-id-type="pmid">8175726</pub-id></mixed-citation></ref><ref id="pone.0188333.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Christensen</surname><given-names>EM</given-names></name>, <name><surname>Patel</surname><given-names>SM</given-names></name>, <name><surname>Korasick</surname><given-names>DA</given-names></name>, <name><surname>Campbell</surname><given-names>AC</given-names></name>, <name><surname>Krause</surname><given-names>KL</given-names></name>, <name><surname>Becker</surname><given-names>DF</given-names></name>, <etal>et al</etal>
<article-title>Resolving the cofactor-binding site in the proline biosynthetic enzyme human pyrroline-5-carboxylate reductase 1</article-title>. <source>J Biol Chem</source>. <year>2017</year>;<volume>292</volume>(<issue>17</issue>):<fpage>7233</fpage>&#x02013;<lpage>43</lpage>. Epub 2017/03/05. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.M117.780288">10.1074/jbc.M117.780288</ext-link></comment> ; PubMed Central PMCID: PMCPMC5409489.<?supplied-pmid 28258219?><pub-id pub-id-type="pmid">28258219</pub-id></mixed-citation></ref><ref id="pone.0188333.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Mackinnon</surname><given-names>AL</given-names></name>, <name><surname>Paavilainen</surname><given-names>VO</given-names></name>, <name><surname>Sharma</surname><given-names>A</given-names></name>, <name><surname>Hegde</surname><given-names>RS</given-names></name>, <name><surname>Taunton</surname><given-names>J</given-names></name>. <article-title>An allosteric Sec61 inhibitor traps nascent transmembrane helices at the lateral gate</article-title>. <source>eLife</source>. <year>2014</year>;<volume>3</volume>:<fpage>e01483</fpage> Epub 2014/02/06. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.7554/eLife.01483">10.7554/eLife.01483</ext-link></comment> ; PubMed Central PMCID: PMCPMC3913039.<?supplied-pmid 24497544?><pub-id pub-id-type="pmid">24497544</pub-id></mixed-citation></ref><ref id="pone.0188333.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Jacobsson</surname><given-names>JA</given-names></name>, <name><surname>Haitina</surname><given-names>T</given-names></name>, <name><surname>Lindblom</surname><given-names>J</given-names></name>, <name><surname>Fredriksson</surname><given-names>R</given-names></name>. <article-title>Identification of six putative human transporters with structural similarity to the drug transporter SLC22 family</article-title>. <source>Genomics</source>. <year>2007</year>;<volume>90</volume>(<issue>5</issue>):<fpage>595</fpage>&#x02013;<lpage>609</lpage>. Epub 2007/08/24. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.ygeno.2007.03.017">10.1016/j.ygeno.2007.03.017</ext-link></comment> .<?supplied-pmid 17714910?><pub-id pub-id-type="pmid">17714910</pub-id></mixed-citation></ref><ref id="pone.0188333.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Iida</surname><given-names>R</given-names></name>, <name><surname>Ueki</surname><given-names>M</given-names></name>, <name><surname>Yasuda</surname><given-names>T</given-names></name>. <article-title>A novel transcriptional repressor, Rhit, is involved in heat-inducible and age-dependent expression of Mpv17-like protein, a participant in reactive oxygen species metabolism</article-title>. <source>Mol Cell Biol</source>. <year>2010</year>;<volume>30</volume>(<issue>10</issue>):<fpage>2306</fpage>&#x02013;<lpage>15</lpage>. Epub 2010/03/17. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/MCB.01025-09">10.1128/MCB.01025-09</ext-link></comment> ; PubMed Central PMCID: PMCPMC2863700.<?supplied-pmid 20231359?><pub-id pub-id-type="pmid">20231359</pub-id></mixed-citation></ref><ref id="pone.0188333.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Martin</surname><given-names>A</given-names></name>, <name><surname>Lemon</surname><given-names>SM</given-names></name>. <article-title>Hepatitis A virus: from discovery to vaccines</article-title>. <source>Hepatology</source>. <year>2006</year>;<volume>43</volume>(<issue>2</issue> Suppl 1):<fpage>S164</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/hep.21052">10.1002/hep.21052</ext-link></comment> .<?supplied-pmid 16447259?><pub-id pub-id-type="pmid">16447259</pub-id></mixed-citation></ref><ref id="pone.0188333.ref040"><label>40</label><mixed-citation publication-type="journal"><name><surname>Chavas</surname><given-names>LM</given-names></name>, <name><surname>Tringali</surname><given-names>C</given-names></name>, <name><surname>Fusi</surname><given-names>P</given-names></name>, <name><surname>Venerando</surname><given-names>B</given-names></name>, <name><surname>Tettamanti</surname><given-names>G</given-names></name>, <name><surname>Kato</surname><given-names>R</given-names></name>, <etal>et al</etal>
<article-title>Crystal structure of the human cytosolic sialidase Neu2. Evidence for the dynamic nature of substrate recognition</article-title>. <source>J Biol Chem</source>. <year>2005</year>;<volume>280</volume>(<issue>1</issue>):<fpage>469</fpage>&#x02013;<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1074/jbc.M411506200">10.1074/jbc.M411506200</ext-link></comment> .<?supplied-pmid 15501818?><pub-id pub-id-type="pmid">15501818</pub-id></mixed-citation></ref><ref id="pone.0188333.ref041"><label>41</label><mixed-citation publication-type="journal"><name><surname>Gayther</surname><given-names>SA</given-names></name>, <name><surname>Batley</surname><given-names>SJ</given-names></name>, <name><surname>Linger</surname><given-names>L</given-names></name>, <name><surname>Bannister</surname><given-names>A</given-names></name>, <name><surname>Thorpe</surname><given-names>K</given-names></name>, <name><surname>Chin</surname><given-names>SF</given-names></name>, <etal>et al</etal>
<article-title>Mutations truncating the EP300 acetylase in human cancers</article-title>. <source>Nat Genet</source>. <year>2000</year>;<volume>24</volume>(<issue>3</issue>):<fpage>300</fpage>&#x02013;<lpage>3</lpage>. Epub 2000/03/04. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/73536">10.1038/73536</ext-link></comment> .<?supplied-pmid 10700188?><pub-id pub-id-type="pmid">10700188</pub-id></mixed-citation></ref><ref id="pone.0188333.ref042"><label>42</label><mixed-citation publication-type="journal"><name><surname>Wearing</surname><given-names>HJ</given-names></name>, <name><surname>Robert</surname><given-names>MA</given-names></name>, <name><surname>Christofferson</surname><given-names>RC</given-names></name>. <article-title>Dengue and chikungunya: modelling the expansion of mosquito-borne viruses into naive populations</article-title>. <source>Parasitology</source>. <year>2016</year>:<fpage>1</fpage>&#x02013;<lpage>14</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1017/S0031182016000421">10.1017/S0031182016000421</ext-link></comment> .<?supplied-pmid 27045211?><pub-id pub-id-type="pmid">27045211</pub-id></mixed-citation></ref><ref id="pone.0188333.ref043"><label>43</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>YJ</given-names></name>, <name><surname>Higgs</surname><given-names>S</given-names></name>, <name><surname>Horne</surname><given-names>KM</given-names></name>, <name><surname>Vanlandingham</surname><given-names>DL</given-names></name>. <article-title>Flavivirus-mosquito interactions</article-title>. <source>Viruses</source>. <year>2014</year>;<volume>6</volume>(<issue>11</issue>):<fpage>4703</fpage>&#x02013;<lpage>30</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3390/v6114703">10.3390/v6114703</ext-link></comment> ; PubMed Central PMCID: PMC4246245.<?supplied-pmid 25421894?><pub-id pub-id-type="pmid">25421894</pub-id></mixed-citation></ref><ref id="pone.0188333.ref044"><label>44</label><mixed-citation publication-type="journal"><name><surname>Smith</surname><given-names>DR</given-names></name>. <article-title>Waiting in the wings: The potential of mosquito transmitted flaviviruses to emerge</article-title>. <source>Critical reviews in microbiology</source>. <volume>2016</volume>:<fpage>1</fpage>&#x02013;<lpage>18</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/1040841X.2016.1230974">10.1080/1040841X.2016.1230974</ext-link></comment> PubMed PMID: 27800692.</mixed-citation></ref><ref id="pone.0188333.ref045"><label>45</label><mixed-citation publication-type="journal"><name><surname>Milstien</surname><given-names>J</given-names></name>, <name><surname>Grachev</surname><given-names>V</given-names></name>, <name><surname>Padilla</surname><given-names>A</given-names></name>, <name><surname>Griffiths</surname><given-names>E</given-names></name>. <article-title>WHO activities towards the three Rs in the development and control of biological products</article-title>. <source>Developments in biological standardization</source>. <year>1996</year>;<volume>86</volume>:<fpage>31</fpage>&#x02013;<lpage>9</lpage>. .<?supplied-pmid 8785961?><pub-id pub-id-type="pmid">8785961</pub-id></mixed-citation></ref><ref id="pone.0188333.ref046"><label>46</label><mixed-citation publication-type="journal"><name><surname>Santak</surname><given-names>M</given-names></name>, <name><surname>Markusic</surname><given-names>M</given-names></name>, <name><surname>Balija</surname><given-names>ML</given-names></name>, <name><surname>Kopac</surname><given-names>SK</given-names></name>, <name><surname>Jug</surname><given-names>R</given-names></name>, <name><surname>Orvell</surname><given-names>C</given-names></name>, <etal>et al</etal>
<article-title>Accumulation of defective interfering viral particles in only a few passages in Vero cells attenuates mumps virus neurovirulence</article-title>. <source>Microbes and infection</source>. <year>2015</year>;<volume>17</volume>(<issue>3</issue>):<fpage>228</fpage>&#x02013;<lpage>36</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.micinf.2014.11.006">10.1016/j.micinf.2014.11.006</ext-link></comment> .<?supplied-pmid 25479555?><pub-id pub-id-type="pmid">25479555</pub-id></mixed-citation></ref><ref id="pone.0188333.ref047"><label>47</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>L</given-names></name>, <name><surname>Zhu</surname><given-names>L</given-names></name>, <name><surname>Zhu</surname><given-names>H</given-names></name>. <article-title>Efficacy of varicella (VZV) vaccination: an update for the clinician</article-title>. <source>Therapeutic advances in vaccines</source>. <year>2016</year>;<volume>4</volume>(<issue>1&#x02013;2</issue>):<fpage>20</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1177/2051013616655980">10.1177/2051013616655980</ext-link></comment> ; PubMed Central PMCID: PMC4976721.<?supplied-pmid 27551429?><pub-id pub-id-type="pmid">27551429</pub-id></mixed-citation></ref><ref id="pone.0188333.ref048"><label>48</label><mixed-citation publication-type="journal"><name><surname>Grahn</surname><given-names>A</given-names></name>, <name><surname>Studahl</surname><given-names>M</given-names></name>. <article-title>Varicella-zoster virus infections of the central nervous system&#x02014;Prognosis, diagnostics and treatment</article-title>. <source>The Journal of infection</source>. <year>2015</year>;<volume>71</volume>(<issue>3</issue>):<fpage>281</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jinf.2015.06.004">10.1016/j.jinf.2015.06.004</ext-link></comment> .<?supplied-pmid 26073188?><pub-id pub-id-type="pmid">26073188</pub-id></mixed-citation></ref><ref id="pone.0188333.ref049"><label>49</label><mixed-citation publication-type="journal"><name><surname>Keating</surname><given-names>GM</given-names></name>. <article-title>Shingles (Herpes Zoster) Vaccine (Zostavax((R))): A Review in the Prevention of Herpes Zoster and Postherpetic Neuralgia</article-title>. <source>BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy</source>. <year>2016</year>;<volume>30</volume>(<issue>3</issue>):<fpage>243</fpage>&#x02013;<lpage>54</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40259-016-0180-7">10.1007/s40259-016-0180-7</ext-link></comment> .<?supplied-pmid 27189459?><pub-id pub-id-type="pmid">27189459</pub-id></mixed-citation></ref><ref id="pone.0188333.ref050"><label>50</label><mixed-citation publication-type="journal"><name><surname>Lambert</surname><given-names>N</given-names></name>, <name><surname>Strebel</surname><given-names>P</given-names></name>, <name><surname>Orenstein</surname><given-names>W</given-names></name>, <name><surname>Icenogle</surname><given-names>J</given-names></name>, <name><surname>Poland</surname><given-names>GA</given-names></name>. <article-title>Rubella</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>385</volume>(<issue>9984</issue>):<fpage>2297</fpage>&#x02013;<lpage>307</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/S0140-6736(14)60539-0">10.1016/S0140-6736(14)60539-0</ext-link></comment> ; PubMed Central PMCID: PMC4514442.<?supplied-pmid 25576992?><pub-id pub-id-type="pmid">25576992</pub-id></mixed-citation></ref><ref id="pone.0188333.ref051"><label>51</label><mixed-citation publication-type="journal"><name><surname>Desmyter</surname><given-names>J</given-names></name>, <name><surname>Melnick</surname><given-names>JL</given-names></name>, <name><surname>Rawls</surname><given-names>WE</given-names></name>. <article-title>Defectiveness of interferon production and of rubella virus interference in a line of African green monkey kidney cells (Vero)</article-title>. <source>Journal of virology</source>. <year>1968</year>;<volume>2</volume>(<issue>10</issue>):<fpage>955</fpage>&#x02013;<lpage>61</lpage>. ; PubMed Central PMCID: PMC375423.<?supplied-pmid 4302013?><pub-id pub-id-type="pmid">4302013</pub-id></mixed-citation></ref><ref id="pone.0188333.ref052"><label>52</label><mixed-citation publication-type="journal"><name><surname>Virk</surname><given-names>RK</given-names></name>, <name><surname>Gunalan</surname><given-names>V</given-names></name>, <name><surname>Tambyah</surname><given-names>PA</given-names></name>. <article-title>Influenza infection in human host: challenges in making a better influenza vaccine</article-title>. <source>Expert review of anti-infective therapy</source>. <year>2016</year>;<volume>14</volume>(<issue>4</issue>):<fpage>365</fpage>&#x02013;<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1586/14787210.2016.1155450">10.1586/14787210.2016.1155450</ext-link></comment> .<?supplied-pmid 26885890?><pub-id pub-id-type="pmid">26885890</pub-id></mixed-citation></ref><ref id="pone.0188333.ref053"><label>53</label><mixed-citation publication-type="journal"><name><surname>Lessler</surname><given-names>J</given-names></name>, <name><surname>Chaisson</surname><given-names>LH</given-names></name>, <name><surname>Kucirka</surname><given-names>LM</given-names></name>, <name><surname>Bi</surname><given-names>Q</given-names></name>, <name><surname>Grantz</surname><given-names>K</given-names></name>, <name><surname>Salje</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Assessing the global threat from Zika virus</article-title>. <source>Science</source>. <year>2016</year>;<volume>353</volume>(<issue>6300</issue>):<fpage>aaf8160</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/science.aaf8160">10.1126/science.aaf8160</ext-link></comment> .<?supplied-pmid 27417495?><pub-id pub-id-type="pmid">27417495</pub-id></mixed-citation></ref><ref id="pone.0188333.ref054"><label>54</label><mixed-citation publication-type="journal"><name><surname>Goebel</surname><given-names>S</given-names></name>, <name><surname>Snyder</surname><given-names>B</given-names></name>, <name><surname>Sellati</surname><given-names>T</given-names></name>, <name><surname>Saeed</surname><given-names>M</given-names></name>, <name><surname>Ptak</surname><given-names>R</given-names></name>, <name><surname>Murray</surname><given-names>M</given-names></name>, <etal>et al</etal>
<article-title>A sensitive virus yield assay for evaluation of Antivirals against Zika Virus</article-title>. <source>Journal of virological methods</source>. <year>2016</year>;<volume>238</volume>:<fpage>13</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jviromet.2016.09.015">10.1016/j.jviromet.2016.09.015</ext-link></comment> .<?supplied-pmid 27678028?><pub-id pub-id-type="pmid">27678028</pub-id></mixed-citation></ref><ref id="pone.0188333.ref055"><label>55</label><mixed-citation publication-type="journal"><name><surname>Kuo</surname><given-names>ML</given-names></name>, <name><surname>Lee</surname><given-names>MB</given-names></name>, <name><surname>Tang</surname><given-names>M</given-names></name>, <name><surname>den Besten</surname><given-names>W</given-names></name>, <name><surname>Hu</surname><given-names>S</given-names></name>, <name><surname>Sweredoski</surname><given-names>MJ</given-names></name>, <etal>et al</etal>
<article-title>PYCR1 and PYCR2 Interact and Collaborate with RRM2B to Protect Cells from Overt Oxidative Stress</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>18846</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep18846">10.1038/srep18846</ext-link></comment> ; PubMed Central PMCID: PMC4702135.<?supplied-pmid 26733354?><pub-id pub-id-type="pmid">26733354</pub-id></mixed-citation></ref><ref id="pone.0188333.ref056"><label>56</label><mixed-citation publication-type="journal"><name><surname>Lowy</surname><given-names>RJ</given-names></name>. <article-title>Influenza virus induction of apoptosis by intrinsic and extrinsic mechanisms</article-title>. <source>International reviews of immunology</source>. <year>2003</year>;<volume>22</volume>(<issue>5&#x02013;6</issue>):<fpage>425</fpage>&#x02013;<lpage>49</lpage>. Epub 2003/09/10. .<?supplied-pmid 12959753?><pub-id pub-id-type="pmid">12959753</pub-id></mixed-citation></ref><ref id="pone.0188333.ref057"><label>57</label><mixed-citation publication-type="journal"><name><surname>Iwai</surname><given-names>A</given-names></name>, <name><surname>Shiozaki</surname><given-names>T</given-names></name>, <name><surname>Miyazaki</surname><given-names>T</given-names></name>. <article-title>Relevance of signaling molecules for apoptosis induction on influenza A virus replication</article-title>. <source>Biochemical and biophysical research communications</source>. <year>2013</year>;<volume>441</volume>(<issue>3</issue>):<fpage>531</fpage>&#x02013;<lpage>7</lpage>. Epub 2013/11/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.bbrc.2013.10.100">10.1016/j.bbrc.2013.10.100</ext-link></comment> .<?supplied-pmid 24177013?><pub-id pub-id-type="pmid">24177013</pub-id></mixed-citation></ref><ref id="pone.0188333.ref058"><label>58</label><mixed-citation publication-type="journal"><name><surname>Huang</surname><given-names>CH</given-names></name>, <name><surname>Chen</surname><given-names>CJ</given-names></name>, <name><surname>Yen</surname><given-names>CT</given-names></name>, <name><surname>Yu</surname><given-names>CP</given-names></name>, <name><surname>Huang</surname><given-names>PN</given-names></name>, <name><surname>Kuo</surname><given-names>RL</given-names></name>, <etal>et al</etal>
<article-title>Caspase-1 deficient mice are more susceptible to influenza A virus infection with PA variation</article-title>. <source>The Journal of infectious diseases</source>. <year>2013</year>;<volume>208</volume>(<issue>11</issue>):<fpage>1898</fpage>&#x02013;<lpage>905</lpage>. Epub 2013/08/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/infdis/jit381">10.1093/infdis/jit381</ext-link></comment> .<?supplied-pmid 23901080?><pub-id pub-id-type="pmid">23901080</pub-id></mixed-citation></ref><ref id="pone.0188333.ref059"><label>59</label><mixed-citation publication-type="journal"><name><surname>Alsuwaidi</surname><given-names>AR</given-names></name>, <name><surname>Almarzooqi</surname><given-names>S</given-names></name>, <name><surname>Albawardi</surname><given-names>A</given-names></name>, <name><surname>Benedict</surname><given-names>S</given-names></name>, <name><surname>Kochiyil</surname><given-names>J</given-names></name>, <name><surname>Mustafa</surname><given-names>F</given-names></name>, <etal>et al</etal>
<article-title>Cellular bioenergetics, caspase activity and glutathione in murine lungs infected with influenza A virus</article-title>. <source>Virology</source>. <year>2013</year>;<volume>446</volume>(<issue>1&#x02013;2</issue>):<fpage>180</fpage>&#x02013;<lpage>8</lpage>. Epub 2013/10/01. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.virol.2013.07.034">10.1016/j.virol.2013.07.034</ext-link></comment> .<?supplied-pmid 24074580?><pub-id pub-id-type="pmid">24074580</pub-id></mixed-citation></ref><ref id="pone.0188333.ref060"><label>60</label><mixed-citation publication-type="journal"><name><surname>Muhlbauer</surname><given-names>D</given-names></name>, <name><surname>Dzieciolowski</surname><given-names>J</given-names></name>, <name><surname>Hardt</surname><given-names>M</given-names></name>, <name><surname>Hocke</surname><given-names>A</given-names></name>, <name><surname>Schierhorn</surname><given-names>KL</given-names></name>, <name><surname>Mostafa</surname><given-names>A</given-names></name>, <etal>et al</etal>
<article-title>Influenza virus-induced caspase-dependent enlargement of nuclear pores promotes nuclear export of viral ribonucleoprotein complexes</article-title>. <source>Journal of virology</source>. <year>2015</year>;<volume>89</volume>(<issue>11</issue>):<fpage>6009</fpage>&#x02013;<lpage>21</lpage>. Epub 2015/03/27. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/JVI.03531-14">10.1128/JVI.03531-14</ext-link></comment> ; PubMed Central PMCID: PMCPMC4442457.<?supplied-pmid 25810542?><pub-id pub-id-type="pmid">25810542</pub-id></mixed-citation></ref><ref id="pone.0188333.ref061"><label>61</label><mixed-citation publication-type="journal"><name><surname>Bauer</surname><given-names>RN</given-names></name>, <name><surname>Brighton</surname><given-names>LE</given-names></name>, <name><surname>Mueller</surname><given-names>L</given-names></name>, <name><surname>Xiang</surname><given-names>Z</given-names></name>, <name><surname>Rager</surname><given-names>JE</given-names></name>, <name><surname>Fry</surname><given-names>RC</given-names></name>, <etal>et al</etal>
<article-title>Influenza enhances caspase-1 in bronchial epithelial cells from asthmatic volunteers and is associated with pathogenesis</article-title>. <source>The Journal of allergy and clinical immunology</source>. <year>2012</year>;<volume>130</volume>(<issue>4</issue>):<fpage>958</fpage>&#x02013;<lpage>67.e14</lpage>. Epub 2012/10/02. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jaci.2012.07.013">10.1016/j.jaci.2012.07.013</ext-link></comment> ; PubMed Central PMCID: PMCPMC3470476.<?supplied-pmid 23021143?><pub-id pub-id-type="pmid">23021143</pub-id></mixed-citation></ref><ref id="pone.0188333.ref062"><label>62</label><mixed-citation publication-type="journal"><name><surname>Nagarajan</surname><given-names>MM</given-names></name>, <name><surname>Kibenge</surname><given-names>FS</given-names></name>. <article-title>A novel technique for in-vivo assay of viral regulatory regions in genomes of animal RNA viruses</article-title>. <source>Journal of virological methods</source>. <year>1998</year>;<volume>72</volume>(<issue>1</issue>):<fpage>51</fpage>&#x02013;<lpage>8</lpage>. .<?supplied-pmid 9672132?><pub-id pub-id-type="pmid">9672132</pub-id></mixed-citation></ref><ref id="pone.0188333.ref063"><label>63</label><mixed-citation publication-type="journal"><name><surname>Scott</surname><given-names>LJ</given-names></name>. <article-title>Tetravalent Dengue Vaccine: A Review in the Prevention of Dengue Disease</article-title>. <source>Drugs</source>. <year>2016</year>;<volume>76</volume>(<issue>13</issue>):<fpage>1301</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/s40265-016-0626-8">10.1007/s40265-016-0626-8</ext-link></comment> .<?supplied-pmid 27506852?><pub-id pub-id-type="pmid">27506852</pub-id></mixed-citation></ref><ref id="pone.0188333.ref064"><label>64</label><mixed-citation publication-type="journal"><name><surname>Wichmann</surname><given-names>O</given-names></name>, <name><surname>Vannice</surname><given-names>K</given-names></name>, <name><surname>Asturias</surname><given-names>EJ</given-names></name>, <name><surname>de Albuquerque Luna</surname><given-names>EJ</given-names></name>, <name><surname>Longini</surname><given-names>I</given-names></name>, <name><surname>Lopez</surname><given-names>AL</given-names></name>, <etal>et al</etal>
<article-title>Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>42</issue>):<fpage>5535</fpage>&#x02013;<lpage>42</lpage>. Epub 2017/09/13. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2017.08.066">10.1016/j.vaccine.2017.08.066</ext-link></comment> .<?supplied-pmid 28893477?><pub-id pub-id-type="pmid">28893477</pub-id></mixed-citation></ref><ref id="pone.0188333.ref065"><label>65</label><mixed-citation publication-type="journal"><name><surname>Cassone</surname><given-names>A</given-names></name>, <name><surname>Rappuoli</surname><given-names>R</given-names></name>. <article-title>Universal vaccines: shifting to one for many</article-title>. <source>mBio</source>. <year>2010</year>;<volume>1</volume>(<issue>1</issue>). <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1128/mBio.00042-10">10.1128/mBio.00042-10</ext-link></comment> ; PubMed Central PMCID: PMC2912660.<?supplied-pmid 20689748?><pub-id pub-id-type="pmid">20689748</pub-id></mixed-citation></ref><ref id="pone.0188333.ref066"><label>66</label><mixed-citation publication-type="journal"><name><surname>Music</surname><given-names>S</given-names></name>. <article-title>Governments, off-patent vaccines, smallpox and universal childhood vaccination</article-title>. <source>Vaccine</source>. <year>2010</year>;<volume>28</volume>(<issue>4</issue>):<fpage>869</fpage>&#x02013;<lpage>72</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2009.08.006">10.1016/j.vaccine.2009.08.006</ext-link></comment> .<?supplied-pmid 19699330?><pub-id pub-id-type="pmid">19699330</pub-id></mixed-citation></ref><ref id="pone.0188333.ref067"><label>67</label><mixed-citation publication-type="journal"><name><surname>Zhou</surname><given-names>H</given-names></name>, <name><surname>Huang</surname><given-names>Y</given-names></name>, <name><surname>Yuan</surname><given-names>S</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Wu</surname><given-names>S</given-names></name>, <name><surname>Xu</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Sequential immunization with consensus influenza hemagglutinins raises cross-reactive neutralizing antibodies against various heterologous HA strains</article-title>. <source>Vaccine</source>. <year>2017</year>;<volume>35</volume>(<issue>2</issue>):<fpage>305</fpage>&#x02013;<lpage>12</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.vaccine.2016.11.051">10.1016/j.vaccine.2016.11.051</ext-link></comment> .<?supplied-pmid 27914743?><pub-id pub-id-type="pmid">27914743</pub-id></mixed-citation></ref><ref id="pone.0188333.ref068"><label>68</label><mixed-citation publication-type="journal"><name><surname>Vincent-Falquet</surname><given-names>JC</given-names></name>, <name><surname>Peyron</surname><given-names>L</given-names></name>, <name><surname>Souvras</surname><given-names>M</given-names></name>, <name><surname>Moulin</surname><given-names>JC</given-names></name>, <name><surname>Tektoff</surname><given-names>J</given-names></name>, <name><surname>Patet</surname><given-names>J</given-names></name>. <article-title>Qualification of working cell banks for the Vero cell line to produce licensed human vaccines</article-title>. <source>Developments in biological standardization</source>. <year>1989</year>;<volume>70</volume>:<fpage>153</fpage>&#x02013;<lpage>6</lpage>. .<?supplied-pmid 2759347?><pub-id pub-id-type="pmid">2759347</pub-id></mixed-citation></ref><ref id="pone.0188333.ref069"><label>69</label><mixed-citation publication-type="journal"><name><surname>Moore</surname><given-names>AE</given-names></name>, <name><surname>Sabachewsky</surname><given-names>L</given-names></name>, <name><surname>Toolan</surname><given-names>HW</given-names></name>. <article-title>Culture characteristics of four permanent lines of human cancer cells</article-title>. <source>Cancer research</source>. <year>1955</year>;<volume>15</volume>(<issue>9</issue>):<fpage>598</fpage>&#x02013;<lpage>602</lpage>. .<?supplied-pmid 13261081?><pub-id pub-id-type="pmid">13261081</pub-id></mixed-citation></ref><ref id="pone.0188333.ref070"><label>70</label><mixed-citation publication-type="journal"><name><surname>Kirkwood</surname><given-names>CD</given-names></name>, <name><surname>Bishop</surname><given-names>RF</given-names></name>, <name><surname>Coulson</surname><given-names>BS</given-names></name>. <article-title>Attachment and growth of human rotaviruses RV-3 and S12/85 in Caco-2 cells depend on VP4</article-title>. <source>Journal of virology</source>. <year>1998</year>;<volume>72</volume>(<issue>11</issue>):<fpage>9348</fpage>&#x02013;<lpage>52</lpage>. ; PubMed Central PMCID: PMC110359.<?supplied-pmid 9765487?><pub-id pub-id-type="pmid">9765487</pub-id></mixed-citation></ref><ref id="pone.0188333.ref071"><label>71</label><mixed-citation publication-type="journal"><name><surname>Suzuki</surname><given-names>R</given-names></name>, <name><surname>de Borba</surname><given-names>L</given-names></name>, <name><surname>Duarte dos Santos</surname><given-names>CN</given-names></name>, <name><surname>Mason</surname><given-names>PW</given-names></name>. <article-title>Construction of an infectious cDNA clone for a Brazilian prototype strain of dengue virus type 1: characterization of a temperature-sensitive mutation in NS1</article-title>. <source>Virology</source>. <year>2007</year>;<volume>362</volume>(<issue>2</issue>):<fpage>374</fpage>&#x02013;<lpage>83</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.virol.2006.11.026">10.1016/j.virol.2006.11.026</ext-link></comment> ; PubMed Central PMCID: PMC2396755.<?supplied-pmid 17289102?><pub-id pub-id-type="pmid">17289102</pub-id></mixed-citation></ref><ref id="pone.0188333.ref072"><label>72</label><mixed-citation publication-type="journal"><name><surname>Feinstone</surname><given-names>SM</given-names></name>, <name><surname>Daemer</surname><given-names>RJ</given-names></name>, <name><surname>Gust</surname><given-names>ID</given-names></name>, <name><surname>Purcell</surname><given-names>RH</given-names></name>. <article-title>Live attenuated vaccine for hepatitis A</article-title>. <source>Developments in biological standardization</source>. <year>1983</year>;<volume>54</volume>:<fpage>429</fpage>&#x02013;<lpage>32</lpage>. .<?supplied-pmid 6317493?><pub-id pub-id-type="pmid">6317493</pub-id></mixed-citation></ref><ref id="pone.0188333.ref073"><label>73</label><mixed-citation publication-type="journal"><name><surname>Lee</surname><given-names>JH</given-names></name>, <name><surname>Lee</surname><given-names>GC</given-names></name>, <name><surname>Kim</surname><given-names>JI</given-names></name>, <name><surname>Yi</surname><given-names>HA</given-names></name>, <name><surname>Lee</surname><given-names>CH</given-names></name>. <article-title>Development of a new cell culture-based method and optimized protocol for the detection of enteric viruses</article-title>. <source>Journal of virological methods</source>. <year>2013</year>;<volume>191</volume>(<issue>1</issue>):<fpage>16</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.jviromet.2013.03.019">10.1016/j.jviromet.2013.03.019</ext-link></comment> .<?supplied-pmid 23578702?><pub-id pub-id-type="pmid">23578702</pub-id></mixed-citation></ref><ref id="pone.0188333.ref074"><label>74</label><mixed-citation publication-type="journal"><name><surname>Andzhaparidze</surname><given-names>OG</given-names></name>, <name><surname>Bogomolova</surname><given-names>NN</given-names></name>, <name><surname>Boriskin</surname><given-names>Yu S</given-names></name>, <name><surname>Drynov</surname><given-names>ID</given-names></name>. <article-title>Chronic non-cytopathic infection of human continuous cell lines with mumps virus</article-title>. <source>Acta virologica</source>. <year>1983</year>;<volume>27</volume>(<issue>4</issue>):<fpage>318</fpage>&#x02013;<lpage>28</lpage>. .<?supplied-pmid 6138995?><pub-id pub-id-type="pmid">6138995</pub-id></mixed-citation></ref><ref id="pone.0188333.ref075"><label>75</label><mixed-citation publication-type="journal"><name><surname>Liebhaber</surname><given-names>H</given-names></name>, <name><surname>Riordan</surname><given-names>JT</given-names></name>, <name><surname>Horstmann</surname><given-names>DM</given-names></name>. <article-title>Replication of rubella virus in a continuous line of African green monkey kidney cells (Vero)</article-title>. <source>Proceedings of the Society for Experimental Biology and Medicine Society for Experimental Biology and Medicine</source>. <year>1967</year>;<volume>125</volume>(<issue>2</issue>):<fpage>636</fpage>&#x02013;<lpage>43</lpage>. .<?supplied-pmid 4961494?><pub-id pub-id-type="pmid">4961494</pub-id></mixed-citation></ref><ref id="pone.0188333.ref076"><label>76</label><mixed-citation publication-type="journal"><name><surname>Westenfeld</surname><given-names>FW</given-names></name>, <name><surname>Winn</surname><given-names>WC</given-names><suffix>Jr</suffix></name>. <article-title>Use of rhesus monkey kidney cells for isolation of varicella-zoster virus</article-title>. <source>American journal of clinical pathology</source>. <year>1994</year>;<volume>102</volume>(<issue>6</issue>):<fpage>733</fpage>&#x02013;<lpage>5</lpage>. .<?supplied-pmid 7801885?><pub-id pub-id-type="pmid">7801885</pub-id></mixed-citation></ref><ref id="pone.0188333.ref077"><label>77</label><mixed-citation publication-type="journal"><name><surname>Agbulos</surname><given-names>DS</given-names></name>, <name><surname>Barelli</surname><given-names>L</given-names></name>, <name><surname>Giordano</surname><given-names>BV</given-names></name>, <name><surname>Hunter</surname><given-names>FF</given-names></name>. <article-title>Zika Virus: Quantification, Propagation, Detection, and Storage</article-title>. <source>Current protocols in microbiology</source>. <year>2016</year>;<volume>43</volume>:<fpage>15D 4 1</fpage>&#x02013;<lpage>D 4 6</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/cpmc.19">10.1002/cpmc.19</ext-link></comment> .<?supplied-pmid 27858969?><pub-id pub-id-type="pmid">27858969</pub-id></mixed-citation></ref><ref id="pone.0188333.ref078"><label>78</label><mixed-citation publication-type="journal"><name><surname>Tripp</surname><given-names>RA</given-names></name>, <name><surname>Tompkins</surname><given-names>SM</given-names></name>. <article-title>Therapeutic applications of RNAi for silencing virus replication</article-title>. <source>Methods in molecular biology</source>. <year>2009</year>;<volume>555</volume>:<fpage>43</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/978-1-60327-295-7_4">10.1007/978-1-60327-295-7_4</ext-link></comment> .<?supplied-pmid 19495687?><pub-id pub-id-type="pmid">19495687</pub-id></mixed-citation></ref><ref id="pone.0188333.ref079"><label>79</label><mixed-citation publication-type="journal"><name><surname>Holmes</surname><given-names>K</given-names></name>, <name><surname>Williams</surname><given-names>CM</given-names></name>, <name><surname>Chapman</surname><given-names>EA</given-names></name>, <name><surname>Cross</surname><given-names>MJ</given-names></name>. <article-title>Detection of siRNA induced mRNA silencing by RT-qPCR: considerations for experimental design</article-title>. <source>BMC research notes</source>. <year>2010</year>;<volume>3</volume>:<fpage>53</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/1756-0500-3-53">10.1186/1756-0500-3-53</ext-link></comment> ; PubMed Central PMCID: PMC2850347.<?supplied-pmid 20199660?><pub-id pub-id-type="pmid">20199660</pub-id></mixed-citation></ref></ref-list></back></article>